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Progression of Prostate cancer (CaP), depends on a complex series of interactions 
between the tumor and extracellular matrix (ECM) leading to tumor growth and 
metastasis. Hyaluronan (HA), an ECM component, is elevated in CaP and its 
accumulation in the tumor microenvironment is dependent on its synthetic enzyme, 
hyaluronan synthase (HAS), and turnover enzyme, hyaluronidase (Hyal). Although Hyal1 
expression can independently prognosticate CaP, and HAS expression shows increase in 
aggressive prostate cancer cells, the functional relevance of this correlation is unexplored. 
In these studies we aim to dissect the roles of HAS and Hyal1 in prostate cancer. 
Stably overexpressed hyaluronan synthases (HAS2, HAS3), and Hyal1, 
individually or concurrently (Hyal1+HAS2 and Hyal1+HAS3) in a non-metastatic 
prostate tumor cell line, were characterized by subcutaneous and orthotopic injections in 
NOD/SCID mice and assayed for cell proliferation, adhesion, and motility in vitro. 
Subcutaneous tumors were larger for Hyal1+HAS2 cells and smaller in Hyal1+HAS3 
cells, potentially due to effective HA dissipation in the former. With orthoptopic 
injections, Hyal1+HAS transfectants were maximally tumorigenic and metastatic. 
Contrastingly, HAS expression suppressed tumor growth and metastasis, while Hyal1 
promoted metastasis without significant tumor growth. These in vitro characterizations 
suggested tumor suppression by HAS was due to reduced growth with slower cell cycle 
kinetics, and the enhanced metastasis of Hyal1+HAS ascribed to increased adhesion and 
motility of the transfectants. 
We tested ERK activation and cell cycle proteins as potential targets and found 
that Hyal1 showed modestly decreased sustained ERK activation compared to HAS3. 
Furthermore, in asynchronous and cycling cells, cyclin-dependent kinase inhibitors 
(CKIs) p21cip and p27kip were elevated with HAS expression while p21cip expression was 
reduced in Hyal1 and Hyal1+HAS3 cells. 
We demonstrate the dual requirement of both HAS and Hyal for maximum 
prostate tumorgenesis and metastasis mediated via altered adhesion, motility, and cell 
cycle progression. Our studies are the first comprehensive examination of the role of 
HAS and Hyal1 in prostate tumor progression thereby establishing a new paradigm for 
HA metabolism in CaP. 
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CHAPTER 1 
 
INTRODUCTION 
2 
1.1 PROSTATE CANCER 
Prostate cancer (CaP) is the second leading cause of cancer death in men in the 
United States. According to American Cancer Society 2008 statistics approximately one 
in six men are diagnosed with CaP. However, molecular mechanisms linked with the 
development and progressions of the disease are complex. Greater mechanistic 
understanding of growth, angiogenesis and invasion processes would aid in early 
detection and identification of prognostic factors, ultimately providing better 
management of the disease in individual cases. 
The prostate gland is a part of the male reproductive system. It is a small exocrine 
gland located at the base of the bladder surrounding the urethra. The main function of the 
gland is to provide secretory proteins for the semen1. Within the gland are secretory 
luminal epithelial cells, basal cells and underlying basement membrane. The secretory 
luminal epithelial cells are androgen dependent and function in the secretion of prostatic 
proteins. The basal cells are present between the luminal cells and basement membrane. 
Androgen independent neuroendocrine cells are a third cell type, interspersed within the 
basal layer, which provide paracrine signals to the luminal cells1,2. 
A relatively unique feature of CaP is the early preservation of epithelial cell 
dependence on androgen hormones1. Androgen ablation by chemical or surgical 
castration leads to regression of the tumor in the earlier stages3. However, chemical and 
surgical castration prolongs the survival by only 10%. Unfortunately this effect is 
transient and a population of androgen independent cells arises, leading to uncontrolled 
growth in the absence of androgens resulting in the relapse of the tumor2. It is believed 
that the proliferation of the prostate cancer cells is relatively low compared to other 
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cancers2. This implies that CaP can go relatively undetected till aggressive and invasive 
form the cancer develops. Another unusual characteristic of prostate cancer is that it is a 
heterogeneous disease, exhibiting glandular tissue disorganization and multiple tumor 
foci with different genetic and/or epigenetic alterations located in the same gland1. The 
therapeutic challenge is to find a proliferation independent strategy that targets aspects of 
tumor progression such as metastasis and angiogenesis in these diverse populations of 
cells. Alternative therapies based on in-depth understanding of prostate cancer are of 
critical importance. The current therapies used for treatment of CaP include 
chemotherapy and radiation therapy. These offer palliative benefits, but do not change the 
life expectancy4. Given that early diagnosis would reduce the mortality associated with 
CaP and enhance life expectancy, discovery of biomarkers for diagnosis and prognosis is 
an important research avenue. 
The prognostic potential of prostate cancer is mainly dictated by the presence or 
absence of metastases1. There is an inverse relationship between tumor differentiation 
and metastasis. Well differentiated tumors rarely metastasize, whereas poorly 
differentiated tumors are always metastatic. The prognostic indicators that have been 
used for organ confined prostate cancer are Gleason score (based on degree of tissue 
disorganization due to heterogeneity)5, tumor volume and Ki-67 index6-8. Progression 
associated prognostic features include Gleason score, stage, capsular invasion and 
Prostate Specific Antigen (PSA). Some biological markers commonly used to detect 
progression are E-cadherin9,10, microvessel density and aneuploidy4. Since none of these 
is effective in all cases, there is a need for markers which will determine aggressive 
disease in the early stages of development. 
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1.2 HYALURONAN 
Extracellular matrix (ECM) is defined as a complex mixture of proteins, 
proteoglycans, and glycosaminoglycans. It is well established that ECM important role in 
tumor progression, especially in cancers such as CaP that are of epithelial origin. The 
ECM can modulate cell behaviors to maintain tissue architecture and cell adhesion, 
sustain cell proliferation, or signal cell death. Tumor progression occurs with constant 
interaction between the cancerous cells and the ECM. In fact, remodeling and changes in 
the ECM are important pre-requisites for tumor progression11,12. 
Hyaluronan (HA) is a critical element of the ECM, shown to be involved in 
CaP13-16. HA was first described by Meyer and Palmer17 as a polysaccharide found in the 
vitreous humor of the bovine eye. The study described in this article mainly focused on 
the physical and chemical properties of HA and defined HA as a high molecular weight 
polymer composed of monomers of glucuronic acid and N-acetylglucosamine linked by 
alternating β-1,3 and β-1,4 linkages17. HA is unique among the various complex 
carbohydrates found in mammals, in that it is not synthesized within the golgi apparatus 
and is not formed on a protein core or complex18,19. In some tissues such as the vitreous, 
synovial and dermis, HA is a mechanical and structural component16. However, it is now 
known to have an active role in modulating cell behavior. 
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1.3 HYALURONAN AND CANCER 
Localization of HA in tumor is dependent on the origin and type of the tumor. 
Normal tissue from simple epithelia such as those of bladder, breast, prostate, ovary and 
colon show very weak signal for HA or sometimes no signal20-24. Development and 
progression of tumors in these tissues is associated with HA accumulation around tumor 
cells and in tumor associated stroma. Tumor grade and differentiation state show positive 
correlation with HA staining intensity25. In ovarian and breast cancers, stromal HA signal 
is an independent prognostic indicator of patient survival. In colorectal and gastric cancer 
tumor cell associated HA correlates with local invasive growth and metastasis to lymph 
nodes and salivary glands20,26-28. In bladder cancer urinary concentration of HA is 
elevated by three to seven fold irrespective of tumor grade and is now being employed as 
a diagnostic and prognostic marker for bladder cancer. 
One of the earliest studies in prostate cancerous tissues indicated that HA 
increased with dedifferentiation of the tumor29. HA levels were elevated seven to eight 
fold in low grade and high grade prostate cancer and metastatic prostate cancer tissues, 
compared to normal prostate and benign prostatic hyperplasia. Aaltoma et al studied 
localization of HA in tumor samples in relationship to other prognostic factors such as 
Gleason score, PSA recurrence, seminal vesicle invasion etc. In this case, PSA recurrence 
and other factors related to unfavorable prognosis were predicted by strong stromal HA30. 
Similar studies were conducted by several other researchers with a longer follow-up 
period. Interestingly, these studies found that combined HA-HYAL1 (HYAL1 
hyaluronidase) staining predicted progression along with PSA, Gleason score, disease 
stage and seminal vesicle invasion15. Thus, a high level of HA on tumor cells and 
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intratumoral stromal cells may indicate poor patient outcome or reduced disease-free 
survival period, specifically true for bladder, prostate, breast, gastric, and colorectal 
cancers. 
 
1.4 HYALURONAN METABOLISM 
HA is abundantly turned over, with a half-life of 1-3 days in cartilage and less 
than one day in the skin epidermis31,32. Proteins that synthesize HA are called hyaluronan 
synthases (HAS), proteins that break down or process HA are termed hyaluronidases 
(Hyal), and there are specific receptors which mediate the various biological functions of 
HA. The HA receptors also regulate HA metabolism by internalization and endocytosis. 
 
1.4.1 Hyaluronan Synthases 
HAS enzymes are plasma membrane embedded proteins that polymerize HA by 
alternating β1-4 and β1-3 linked addition of glucuronic acid and N-acetylglucosamine 
from UDP-esterified precursors. There are three distinct isozymes for the HAS, denoted 
as HAS1, HAS2, and HAS3 in mammals. HAS enzymes are intriguing in that a single 
protein forms both glycosidic bonds using two sugar substrates to synthesize HA33. HA 
synthesis occurs at the reducing end of the growing chain by a two-site mechanism34. 
During embryogenesis, the three HAS genes are expressed tissue specifically with 
partially distinct timing35. Only HAS2 is an essential gene, targeted disruption of which 
stops cardiac development36. The three human HAS genes occur on three different 
chromosomes: 19, 8 and 16 for HAS1, HAS2 and HAS3, respectively. The three 
isozymes are 55-71% identical at the amino acid level and ≈30% identical to the 
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prokaryotic proteins19,35,37. The topology of the human HAS enzymes has not been 
experimentally determined, but secondary structure predictions have suggested seven 
transmembrane regions with a central, cytoplasmic loop housing the putative catalytic 
region of the enzyme33,38. Polymerization of HA occurs at the inner cytoplasmic part of 
the membrane and the polymer is extruded out into the extracellular space during 
elongation33,38. 
Although all the three synthases catalyze the same reaction, one study suggested 
that each of the isozymes produces a different size product with slightly different enzyme 
kinetics39. Though range of molecular sizes is overlapping, the average size of HA 
synthesized by HAS1 and HAS2 was reported to be ≈2 million Daltons, whereas that of 
HAS3 was ≈200kDa. 
1.4.1.1 Regulation of Hyaluronan Synthesis 
To date, regulation of HAS has been reported to occur only at the transcriptional 
level in response to various growth factors and cytokines. Upregulation of HAS2 mRNA 
is observed by transforming growth factor beta (TGF-β)40, bone morphogenetic protein 
superfamily members41, interleukin-1 beta (IL-1β)42, epidermal growth factor (EGF)40, 
platelet derived growth factor (PDGF)43,44, insulin-like growth factor-1 (IGF-1) and basic 
fibroblast growth factor (bFGF)45. PDGF-bb stimulated upregulation of HAS2 mRNA in 
smooth muscle cells derived from normal prostate and specimens of Benign Prostatic 
Hyperplasia (BPH). In renal cells, the major regulators of HAS2 promoters were Sp1 and 
Sp2 transcriptional factors46. In mammalian cell cultures, the expression of HAS mRNA 
was also regulated by cell density, where the expression was higher in sub-confluent 
cultures compared to confluent cultures47. 
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HA synthesis is additionally regulated by restricting the availability of HA 
precursors. The enzyme UDP-glucose dehydrogenase catalyzes synthesis of the UDP-
glucuronate precursor, and is regulated by androgens in prostate epithelium48-50. 
Androgen stimulated HA production in the Noble and Dunning rat models of prostate 
carcinoma51. Li, et al, have shown a significant increase in HA staining intensity in 
androgen induced dysplastic and neoplastic rat prostate stroma51. Further evidence of the 
role of androgen in regulating HA accumulation derived from studies in which androgen 
deprivation by castration reduced HA levels in the dorsal rat prostate52,53. 
Clinicopathological studies have shown that elevated HAS1 transcripts and 
intronic gene splicing correlate with poor prognosis in human colon, ovarian cancers and 
multiple myelomas54-56. HAS1 transcript and protein were found elevated in neoplastic 
bladder tissues compared to normal tissues. This suggests that HAS1 is the likely 
candidate contributing to elevated HA levels in high grade bladder cancer57. Though no 
study has been yet reported on HAS expression levels in patient prostate tumor 
specimens, aggressive and metastatic androgen independent prostate cancer cells 
expressed 3-fold and 30-fold higher HAS2 and HAS3 transcripts, respectively58 and 
produce substantially more HA. Genetic variations in chromosome 8q24 have been 
associated with increased risk factor for prostate and colorectal cancer59,60. Since HAS2 is 
located in 8q24 and genetically overrepresented in prostate cancer61, variation in this 
locus might also affect HAS2 expression in cancers and cancer cell lines62. 
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1.4.2 Hyaluronidases 
Six hyaluronidase-like gene sequences have been identified in humans. HYAL1, 
HYAL2 and HYAL3, are located on chromosome 3p21.3. The other three, HYAL4, 
SPAM1, and a pseudogene (“PHYAL”), are located on chromosome 7p31.3. The five 
proteins encoded by these genes are similar in size and share up to 40% amino acid 
identity63-66. PH20, Hyal1, and Hyal2 are relatively well characterized. PH20 (encoded by 
SPAM1) was originally thought to be found only in sperm. Hyal1 and Hyal2 proteins are 
predominantly found in the somatic tissue67-70. Hyal3 knockout mice suggest a potential 
role for this isozyme in health of joint/lung tissue71. Both Hyal3 and Hyal4 appear to lack 
hyaluronidase activity despite conservation of key catalytic residues, but a systematic 
characterization has not been done. 
PH20 is active at neutral pH and facilitates sperm penetration by degrading the 
HA surrounding the cumulus mass of the ovum. It is crucial for fertilization72. PH20 has 
been detected in the epididymis, seminal vesicles, prostate, female genital tract, breast, 
placental and fetal tissues (refs). Hyal1 has high specific activity as a hyaluronidase, but 
only at acidic pH (<4.5). It is a lysosomal protein, but is also found in the serum and 
urine, and is elevated in patients with prostate and bladder cancer14,73,74. Hyal2 is 
anchored to the plasma membrane by a glycosyl-phosphatidylinositol (GPI) moiety, and 
has activity at pH <4.5, as well as >6.075,76. Hyal1 and PH20 cleave HMW HA into 
tetraaccharides77, whereas Hyal2 reportedly cleaves HA to fragments of no less than 
20kDa76. Functional analysis of Hyal1 in our laboratory has experimentally demonstrated 
the essential catalytic residues of the enzyme and determined that glycosylation is not 
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only needed for proper subcellular distribution of Hyal1, but also for its intrinsic catalytic 
activity78. 
1.4.2.1 Hyaluronidases in Tumors 
Loss of chromosome 3p21.3 occurs commonly in some epithelial tumors such as 
lung and breast cancers79,80. For this reason, hyaluronidases were initially termed tumor 
suppressors. Alternative mRNA splicing has been reported for Hyal1 and Hyal3. The 
variants, which were obtained from normal and cancerous bladder tissues and from 
prostate cancer cell lines, encode truncated proteins that lack enzyme activity. The 
significance of such variation is not understood81. 
The concept that both HA and hyaluronidases are jointly required for tumor 
progression has been introduced by several labs, including ours. Hyal1 is the most well 
documented hyaluronidase in cancer but others have not been widely examined. 
Specifically, Hyal1 is elevated in bladder, prostate, head and neck, and squamous cell 
carcinomas14,82,83. Hyal1 levels were significantly elevated in high grade versus low grade 
prostate cancer tissues. Also in comparison, normal prostate and benign prostatic 
hyperplasia had much lower levels of Hyal1 compared to metastatic prostate cancer 
lesions14,73. Similar results were found in bladder cancer specimens74,84-87. Joint 
evaluation of HA and hyaluronidase is marketed as a diagnostic and prognostic test for 
bladder cancer86. 
Hyal2 is important for retro-viral entry and oncogenesis in sheep76,88,89. Although 
normal adult brain is deficient in Hyal2 transcripts, but several glial cell tumors and 
menigiomas show increased transcript levels75,90. No distinct correlation was observed 
with tumor grade or stage. Over-expression of Hyal2 in a mouse astrocytoma cell line 
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accelerates intracerebral growth91,92. Highly invasive breast cancer cell lines were shown 
to express Hyal293. Hyaluronidase similar to the one in sperm head (PH20) was also 
expressed in metastatic melanoma, colon carcinoma and glioblastoma cell lines, but 
absent in normal tissues of the same origin94. PH20 transcript levels were significantly 
elevated in laryngeal cancer specimens compared to their normal counterparts, with 
metastatic lesions showing a higher expression in comparison to the primary tumor95. 
PH20 was elevated in invasive and metastatic breast cancer96. 
 
1.5 HYALURONAN RECEPTORS 
HA elicits specific effects on cell behavior by activating intracellular signaling 
pathways via binding to proteins generally known as hyaladherins97 Receptors such as 
Cluster of Differentiation 44 (CD44) and Receptor for Hyaluronan Mediated Motility 
(RHAMM) are well characterized signaling receptors. More recently, receptors such as 
LYVE1 (Lymphatic Vessel Endothelial Receptor1), HARE (Hyaluronan Receptor for 
Endocytosis) and toll-like receptors TLR1 and TLR4, have been identified. Although 
implicated in cancer processes, particularly in lymphangiogenesis (development of new 
tumor-associated lymphatic vessels), in contrast to CD44 and RHAMM which are 
expressed on the tumor cells, these latter classes of receptors appear primarily to be 
localized in metastatic target tissues and may be counter receptors that mediate tissue-
specific metastasis98-101. Thus, we have confined the scope of our discussion to CD44 and 
RHAMM. 
RHAMM is a HA binding protein with multiple alternatively spliced isoforms 
that reportedly localizes both intracellularly and at the cell surface, though the coding 
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sequence does not contain a signal peptide or a transmembrane domain102. Inside the cell, 
RHAMM occurs in the cytoplasm, mitochondria, and nucleus103-106. RHAMM is 
associated with the cytoskeleton, microtubules, centrosomes and mitotic spindle103,107, 
and apparently influences mitosis by inducing the expression of cell cycle proteins Cdc25 
and Cyclin B1108. Sohr et al109 have shown that RHAMM expression is regulated during 
the various phases of the cell cycle. Resting cells contain very little, but it’s mRNA and 
protein levels rise during DNA synthesis (S-phase) and peak during the mitotic (G2/M) 
phase. The tumor suppressor p53 can down-regulate cell cycle dependent expression of 
RHAMM109. Since Brecht et al, showed increased HA synthesis is required during 
mitosis for cell detachment110, RHAMM-HA cell cycle control may be significant in 
cancer progression. 
RHAMM, is not highly expressed in normal tissues111-113 and is not essential for 
mouse embryonic development and adult mouse homeostasis114,115, but its absence slows 
wound repair and it is overexpressed in several advanced cancers104,116-121. 
Hyperexpression of RHAMM in breast cancer lesions predicts poor clinical outcome and 
increased risk of sporadic lymph node metastasis122,123. Additionally, homozygous 
variation in RHAMM was significantly correlated with early onset breast cancer124. 
HA ligation to the cell surface isoform of RHAMM activates multiple signaling 
pathways to affect cell motility and breast cancer progression113. RHAMM 
overexpression caused and maintained Ras-dependent cell transformation125. In the 
absence of CD44 expression in some advanced cancers, RHAMM is postulated to 
promote HA-mediated cell signaling and oncogenic progression. 
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CD44 is a prominent cell surface HA receptor, a type 1 transmembrane 
glycoprotein that contributes to regulation of growth, survival, differentiation and 
motility. CD44 isoforms are broadly expressed and range in size from ≈80-200kDa. All 
isoforms are encoded by a single gene126 of 20 exons, from which alternatively spliced 
products are generated. The standard isoform of CD44 consists of an N-terminal signal 
sequence (exon 1), a HA binding domain with homology to the link protein family of 
aggrecan and HA binding proteins (exons 2 and 3), a “stem” region of 248 amino acids 
(Exons 4, 5, 16, 17), a 21 amino acid transmembrane domain (exon 18), and a 72 amino 
acid cytoplasmic domain (exon 19). The splice variants are generated as a result of 
insertion of various permutations and combinations of exons 6-15 (v1-v10) into the stem 
region. The variants are most commonly expressed in epithelial cells and are upregulated 
under pathological conditions such as cancer126-128. 
Regulation of CD44 occurs at multiple levels in addition to splicing: promoter 
methylation129-131, transcription132, post-translational modifications such as 
glycosylation133,134, glycosaminoglycan attachment133,134, and phosphorylation135,136, 
ligand binding132, and proteolytic processing of the extracellular domain137. Examination 
of CD44 expression in CaP clinical specimens has produced controversial results. 
Overexpression of CD44 in CaP cell lines suppressed metastatic behavior without 
suppression of in vivo tumorigenesis138. On the other hand, studies have implicated CD44 
in CaP cell proliferation, adhesion and motility in vitro as well as in metastatic 
dissemination in vivo139-143. Such discrepancies may arise from variable detection 
methods or may be indicative of the heterogeneity that is a hallmark of CaP. Patrawala, et 
al, found that highly purified CD44+ CaP cells from xenograft human tumors are 100 
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times more tumorigenic and metastatic than the CD44- CaP cells, reflecting a correlation 
between CD44 expression and an aggressive progenitor cell type144, possibly CaP stem 
cells145. 
CD44 signaling functions can be classified into three categories. Binding of CD44 
to HA is reported to promote HA internalization, facilitating HA degradation and 
constituent sugar salvage146. Recent evidence implicates CD44 in activation of 
hyaluronidases through its interaction with Na+/H+ exchange pumps in coated pit 
microdomains147,148. Hyal1 and Hyal2 are thought to associate inertly with CD44-bound 
HA until activated by the consequent local acidification148. CD44 is reported to locally 
concentrate matrix metalloproteases (MMPs) and growth factor receptors. MMP’s are 
important mediators of tumor cell invasion149. Receptor tyrosine kinases such as SF/HGF 
(c-Met), ERBB1 (EGFR), ERBB2, ERBB3 and ERBB4 growth factor receptors149,150 are 
activated by local clustering151,152. In this way, CD44-HA interaction influences cell 
signaling in tumor cells to promote tumor growth and invasion. Cytoskeletal adaptor 
proteins Src, Rho GTPase, Rho-GDP-dissociation inhibitor (GDI), ankyrin, Ezrin, 
Radixin, Moesin (ERM) and merlin, to name a few, associate with CD44153-156. 
CD44 may additionally interact with integrins, the main cell surface receptors for 
cell-ECM adhesion, but no direct interaction between CD44 and integrins has been 
shown. Stimulation of CD44 by cross-linking with CD44 antibodies or treatment with 
6.9kDa HA induced αLβ2 integrin expression in colon cancer cells and promoted integrin 
activation157. In gastric cancer cells, CD44 interacted with osteopontin (OPN) to activate 
integrins158 and amplify the matrix-derived survival signal. CD44 engagement with OPN 
caused lipid raft domains to become enriched in CD44-Src-integrin β1, supporting a role 
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for CD44-integrin crosstalk in response to the ECM, but the underlying mechanisms are 
not known159. 
 
1.6 HYALURONAN METABOLISM IN CANCER PROGRESSION – 
MOLECULAR MECHANISMS 
Surface retention of HA is a critical determinant for tumor progression. HA is 
anionic, hydrophilic, and viscous in concentrated solutions. HA bound to tumor cell 
CD44 organizes loosely into a HA-rich pericellular matrix. Much of our understanding of 
the role of this tumor cell HA matrix in disease progression has been deduced through 
experimental manipulation of HAS and hyaluronidases in cell culture and animal models, 
or competitive displacement of endogenous HA-receptor interactions. 
 
1.6.1 Tumor Growth and Metastasis 
Overexpression of HAS2 in fibrosarcoma cells increased HA production, 
anchorage independent growth in vitro and tumor size in mouse xenografts in vivo160. The 
increase in tumor size was mainly due to increase in the proliferation index of the tumors 
and not due to accumulation of tumor stroma or angiogenesis. Another study showed that 
mouse mammary carcinoma cells with low surface HA retention were poorly metastatic, 
whereas ectopic expression of HAS1 in these cell lines caused them to form increased 
numbers of metastatic lung nodules161. HA overproduction in non-metastatic cells 
diminishes contact inhibition, promotes cell growth and migration162. Transgenic mice 
overexpressing HAS2 specifically in mammary gland showed increased tumor incidence, 
forming aggressive, poorly differentiated, and vascularized tumors163. Complementary to 
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these studies, antisense inhibition of HAS2 and HAS3 in metastatic prostate carcinoma 
cells reduced subcutaneous and orthotopic tumor growth in NOD/SCID mice164. 
Competitive disruption of CD44-HA ligation was achieved by expression of the CD44 
ectodomain165,166, reducing mammary and melanoma metastasis by apoptosis or cell 
cycle arrest, respectively167. CD44 antibodies168 or HA oligomers169,170 that prevent 
CD44-HA binding also reduce tumor growth and invasion. Inhibition of growth in the 
latter case was mainly due to suppression of the PI3 kinase cell survival pathway169. 
Interestingly, activation of ERBB2 receptor, which is constitutively high in many 
cancers171,172, is mediated by endogenous CD44-HA interaction, and manipulation of 
cells to produce high levels of HA resulted in increased phosphorylation of ERBB2. 
Interfering with endogenous CD44-HA interaction by employing HA oligomers, soluble 
CD44, and siRNA knock-down of CD44 resulted in reduced ERBB2 activation. 
Additionally disruption of such an interaction also causes disassembly of raft associated 
signaling complexes, which contain phosphorylated ERBB2, CD44, Ezrin, PI3kinase and 
cdc37173. 
Though endogenous HA can promote tumorigenesis, some studies have reported 
that large quantities of high molecular weight HA polymers may antagonize cell 
proliferation, while HA of 10-100kDa stimulated endothelial cell growth and 
angiogenesis174. Moreover, even though elevated HA promoted tumor growth, extremely 
high levels were tumor suppressive175. Expressing HAS in glioma cells lacking 
hyaluronidase reduced tumor growth91. Importantly, prognosis of CaP is predicted by 
concurrent HA and Hyal1 staining14,73,176. Thus, use of HA as a growth stimulus is 
somehow dependent on its processing and turnover. 
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Hyal1 has been characterized in prostate tumor cell lines selected to express 
varying levels and found to be dose dependent in its outcomes. In particular, exceedingly 
high expression of Hyal1 beyond levels found in tumors, inhibited tumor proliferation by 
causing apoptosis176. Hyal1 transfectants with hyaluronidase activities in the range found 
in clinical prostate cancer samples, on the other hand, yielded larger tumors. Thus, 
despite previous studies by other groups in which overexpression of hyaluronidase 
suppressed tumor growth, it is most accurately considered a tumor promoter, at least in 
prostate cancer176-180. Inhibiting Hyal1 expression in bladder and prostate cancer cells 
reduced tumor cell proliferation specifically by cell cycle arrest at G2/M phase181. 
Moreover, Hyal1 expression in oral cancer cells caused an increase in the percentage of 
cells in S-phase, suggesting Hyal1 promotes cell cycle progression and accelerated S-
phase entry, through an unknown mechanism68. 
Expression of Hyal1 in a human non-metastatic prostate cancer cell line induced 
spontaneous metastasis to lymph nodes in mice, though primary tumor growth was 
unaffected182. Hyal1 overexpression in highly metastatic PC3M prostate tumor cells 
increased their metastatic frequency183. Our lab has since determined that, in fact, 
coexpression of HAS and Hyal1 is maximally tumorigenic and metastatic, whereas 
expression of the HAS enzymes individually is poorly tumorigenic and metastatic184,185. 
Adhesion and motility of tumor cells are component processes of tumor invasion 
and metastasis. In wound healing and inflammation, adhesion to HA arrests circulating 
leukocytes in tissues spaces and endothelial cells via its surface receptor CD44186,187. This 
may also be a mechanism exploited by circulating tumor cells that metastasize to remote 
sites188. The pericellular HA matrix can mediate both adhesion and de-adhesion, which 
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would be required at the metastatic site. During cell division, increased HA synthesis in 
G2/M phase causes rounding and mitotic cell detachment189,190. Another study 
demonstrated the significance plasma membrane residence of HAS and HA in formation 
of cell protrusions191. Hyaluronidases are likely to be involved in modulating the pro and 
anti-adhesive functions of HA. 
In cardiac morphogenesis, HA receptor engagement and ras activation were 
shown to promote motility of endothelial cells and induce epithelial mesenchymal 
transition (EMT)36,192, which is also a hallmark of aggressive tumor cells. Candidate 
signaling pathways include those mediated through CD44 and RHAMM. Rho GTPases 
such as Rho and Rac1 participate in the interaction of CD44 with cytoskeleton proteins 
such as ankyrin, ezrin and merlin. This promotes or suppresses Rac1 activation, which 
signals cell motility by inducing focal adhesion turnover, membrane ruffling, cell 
spreading, and formation of cellular protrusions153,193 via FAK (focal adhesion 
kinase)125,194, Src195, and Erk196. 
 
1.6.2 Tumor Angiogenesis 
Angiogenesis is critical for tumor growth, invasion, and metastasis. 
Immunohistochemical studies have shown that the microvessel density is enhanced in 
prostate cancer tissue compared to benign prostatic hyperplasia (BPH) and normal 
prostate tissue197,198. Moreover prostate cancer that metastasized and showed clinical 
symptoms have greater capillary density ratios compared to localized or undetected 
prostate cancer199,200. Various studies have suggested that microvessel density is an 
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independent predictor of prostate cancer progression and a prognostic indicator of 
clinically localized disease201-203. 
Studies have implicated HA in normal wound healing, where it correlates with 
embryonic scarless healing. The role of HA is highly complex and appears to be is 
largely dependent on HA concentration and size204. HA oligosaccharides (6-20 sugars) 
enhanced proliferation and migration of bovine aortic endothelial cells (BAEC) in 
vitro205,206 and promoted collagen synthesis207. In contrast, native high molecular weight 
HA was anti-angiogenic, inhibiting endothelial cell proliferation, migration and capillary 
formation in a three dimensional collagen gel model174,208,209. In inflammatory and wound 
healing responses, HA oligosaccharides indirectly activated endothelial cells by 
stimulating cytokine release (TNF-α, IGF-1, IL-8 and IL1-β) from macrophages210. 
In pathological conditions such as cancer, increased staining of HA of 
undetermined size is observed both in intra and peri-tumoral regions. Its origin is 
uncertain and may be tumor cells, macrophages, activated stromal cells, or other cell 
type. Nevertheless several groups have examined a correlation between HA and tumor 
vascularization211. The biological processes that generate HA oligomers may be by 
hyaluronidases, mechanical shearing, and breakdown by reactive oxygen species (ROS) 
during inflammation, or release of degraded HA from necrotic cells. Cancers such as 
breast212, bladder74, prostate14, and endometrial213 showed increased expression of 
hyaluronidase, which may generate HA oligosaccharides, correlating with increased 
tumor vascularization. Consistent with this notion, antisense mediated knockdown of HA 
synthesizing enzymes HAS2 and HAS3 in aggressive prostate carcinoma cell lines 
reduced tumor vascularization164. Coinjection of exogenous HA with these cell lines 
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restored growth and vascularization in vivo. One possible explanation is that 
hyaluronidase uses this added substrate to make HA oligosaccharides, which affect 
angiogenesis. 
To summarize the role of HA in prostate cancer progression is complex involving 
an interplay between the hyaluronan synthases, hyaluronidases and the HA receptors, 
jointly modulating tumor growth, metastasis and angiogenesis (Figure 1.1). 
 
1.7 MOLECULAR PATHWAYS REGULATING CELL PROLIFERATION 
The basic cell cycle is divided into four phases: DNA synthesis (S phase), in 
which a single copy of error free genetic material is made; mitosis (M phase), in which 
genetic material, cytoplasm, and other cellular components are divided into two identical 
cells; and two gap phases (G1 and G2). In G1, the cell completes proofreading and 
damage correction from the previous round of cell division in preparation for S-phase. In 
G2, the cell reconciles DNA crossovers and prepares for successful completion of 
mitosis214,215. When cells exit the cycle and remain in a non-dividing phase, it is known 
as G0. The various phases are interspersed with certain regulatory checkpoints that 
prevent them from entering into a new phase until successful completion of previous 
phase. This ensures the proper progression through the cell cycle216. Mitogens and cell 
adhesion to ECM control the progression through the G1 phase of the cell cycle, by 
modulating the expression and protein levels of the cyclins and cyclin dependent 
kinases217. 
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Figure 1.1 Model for HA involvement in tumor biology. HA produced by tumor cells 
influences tumor cell proliferation and motility. HA is degraded by the enzyme 
hyaluronidase and other mediators such as reactive oxygen species (ROS), hypoxia and 
also due to necrosis to form small polymers or oligosaccharides. This processing may be 
initiated extracellularly by Hyal1 and/or Hyal2 and continued intracellularly following 
endosomal uptake by cell surface HA receptors. Disruption of HA polymer/receptor 
ligation (RHAMM, CD44) by exposure to HA oligos may trigger signaling in tumor cells 
to initiate proliferation and motility, but also in endothelial cells to promote angiogenesis 
(Figure courtesy from Dr. Melanie A. Simpson). 
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The key molecules that govern the various steps of cell cycle progression include 
the cyclin dependent kinases (CDK), CDK regulators such as cyclins which are the 
activators of CDKs and Cyclin Kinase Inhibitors (CKIs) which inhibit the activity of the 
CDKs. The CDK substrates in G1 are members of the retinoblastoma (Rb) protein 
family218. The CDKs are serine/threonine kinases activated by cyclin binding to 
phosphorylate the Rb proteins. CDK4 and CDK6 form active heterodimeric complexes 
with the D-type cyclins (cyclin D1, D2 and D3). CDK2 is activated by binding to the E-
type cyclins during the G1/S transition and the A-type cyclins during the S phase. 
Collectively, these CDK proteins control the transition from G1 to S phase (Figure 1.2). 
There are two classes of CKIs: the Cip/Kip family and the INK family (INhibitors 
of Kinases). The Cip/Kip proteins p21cip1 (p21) and p27kip1 (p27) mainly inhibit 
CDK2219,220. The CKI p21 acts both by inhibiting CDK2 activity and also by inhibiting 
PCNA, an elongation factor for DNA polymerase δ, thus overall inhibiting progression 
through S-phase. At low concentrations, Cip/Kip proteins promote CDK4 kinase activity 
through the stabilization cyclinD/CDK4 complex. At higher concentrations of CKI, 
however, CDK4 activity is inhibited221. INK4 family proteins p16INK4a (p16), 
p15INK4b (p15), p18INK4c (p18), and p19INK4d (p19) function by inhibiting the CDK4 
and CDK6 – cyclin D1 complex214,222-224. 
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Figure 1.2 Regulation of cell cycle progression via growth factor/ERK signaling. 
ERK is activated in response to growth factors. The cell cycle consists for the DNA-
synthetic phase (S-Phase) and the cell division phase (Mitotic phase-M phase). These are 
interspersed by the G1 and G2 gap phases. Activated ERK stimulates expression of 
immediate early genes such as AP-1. Subsequently this induces expression of cyclin 
D(cyclin D1.2.3). The cyclin D-CDK4/6 complex then initiates retinoblastoma (Rb) 
phosphorylation, which activates E2F family of transcription factors and induces 
expression of target genes such as cyclin E. The cyclin E-Cdk2 further enhances 
phosphorylation of Rb and promotes the S-phase entry. The activation and function of the 
cyclin-Cdk complexes are further regulated/inhibited by the p21cip (p21) and p27kip (p27) 
family of cyclin dependent kinase inhibitors (Adapted from242). 
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1.7.1 Growth Factors and Cell Cycle Progression 
Growth factors bind to their cognate receptors on the cell surface, and mediate 
signaling cascades that influence phosphorylation of ERK1/2. Growth factor receptors 
have intrinsic tyrosine kinase activity in their cytoplasmic tail. On binding to growth 
factors, the receptors are autophosphorylated, which allows docking of SH2-domain 
containing adaptor proteins such as Shc and/or Grb2, and activation of the 
Ras/Raf1/MEK/ERK1/2 pathway225-227 (Figure 1.3). Several intracellular pathways are 
activated to promote cell proliferation. For instance EGF and PDGF are capable of 
rescuing serum starved fibroblasts from G0 arrest by initiating proliferation. This occurs 
predominantly through the Ras/Raf/MEK/ERK pathway, but also through PI3-kinase. 
Activated ERK1/2 translocates to the nucleus, phosphorylates the transcription factor 
Elk-1, which is linked to the expression of cyclin D1228,229. There is extensive evidence to 
show that integrin mediated signaling can influence growth factor signaling via this 
cascade to control cell proliferation56,230. 
Fibroblasts and epithelial cells depend on integrin-mediated adhesion and its 
consequent signaling for translation of cyclin D1, expression of cyclin A and 
downregulation of p21 and p27217,231-233. The dual requirement of integrins and growth 
factors for cell cycle progression originates predominantly with the sustained activation 
of the mitogen-activated protein kinases ERK1/2. It has also been shown that other 
pathways triggered through PI3K and Rho family GTPases also regulate cyclin D1 
expression234,235. Rac signaling to cyclin D1 requires NF-κB and results in earlier 
expression of cyclin D1 within G1 phase236,237. 
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Figure 1.3 ERK activation by growth factors by the Ras/Raf/MEK pathway. Growth 
factor (GF) binds to its receptor (GF receptor). Autophosphorylation (Y-p) of the receptor 
on GF binding causes initiation of a cascade involving adaptor proteins Grb2, Sos, and 
Ras. Activated Ras binds to Raf activating it. Activating Raf in turn activates MEK and 
culminates in the activation of ERK and translocation to the nucleus. ERK further 
phosphorylates transcription factor Elk and this causes transcription of immediate early 
genes (IEG). (Modified from231,242). 
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1.7.2 Hyaluronan and Cell Cycle Progression 
HA plays a role in both proliferative and anti-proliferative responses in a size and 
dose dependent manner. This suggests that HA can influence cell cycle progression to 
elicit its effect on cell proliferation. Endogenous CD44-HA interaction has been shown to 
be necessary for constitutive activation of the ERBB2 receptor in colon and mammary 
carcinoma cells173 and also general activation of a number of other growth factor 
receptors such as EGFR, PDGFR-β, IGFR-β both in a ligand dependent and independent 
manner238. Constitutive engagement of CD44 with small quantities of newly synthesized 
HA results in assembly of signaling complexes containing PI3-K, ezrin, and cdc37173. 
This property of HA might be a signal for cell cycle progression in coordination with the 
growth factor signaling pathway. It has been proposed that HA polymer binding to CD44 
antagonizes mitogen induced S-phase entry by inhibiting the mitogen dependent cyclin 
D1 induction and downregulation of p27 in vascular smooth muscle cells239,240. The 
membrane proximal signaling associated with such changes is not understood, but it is 
intriguing to speculate that its effect might be due to differential association of CD44 
with cytoskeletal signaling components such as ezrin or merlin or due to altered 
interaction with growth factor receptors. 
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1.8 RESEARCH GOALS 
Accumulation of HA in patient prostate tumors together with elevated expression 
of Hyal1 is an independent prognostic indicator of CaP progression and poor outcome for 
patients14,15,241. This clinical correlation is consistent in studies which have suggested the 
HA plays an active role in mediating biologic processes such as cell proliferation and 
migration. For instance aggressive CaP cells show upregulation of HAS2 and HAS3 and 
inhibition of these enzymes causes impaired tumor growth and vascularization164 and 
overexpression of HAS has been shown to promote tumorigenesis in many systems160-163. 
Hyal1 overexpression has also shown to promote tumor growth and metastasis176,183, but 
the exact molecular mechanism for tumorigenesis has not been elucidated. Hyal1 could 
potentially act indirectly by generating HA oligomers some of which has potent biologic 
function such as that in angiogenesis94. Studies have shown that HA oligomers are 
angiogenic and induce growth and recruitment of endothelial cells, whereas large HA 
polymers are anti-proliferative, and extremely small fragments of HA are 
apoptotic174,204,206,209. Moreover, Hyal1 could also directly promote tumorigenesis by 
autocrine effects on the tumor cell and presence of HA might be required for optimum 
effect of Hyal. This has been demonstrated, in glioma cells where, excess production of 
HA is tumorigenic only in the presence of Hyal91. This suggests that the outcome of HA 
metabolism in tumor progression could vary depending on the differential expression of 
the HA biosynthetic and processing enzymes. Studies examining the combined roles of 
HAS and Hyal1 in prostate tumor progression are largely unavailable. Thus there is a 
need for systematic assessment of roles of HA biosynthesis and turnover in prostate 
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tumor biology, particularly with respect to the molecular principles governing tumor 
progression and to determine the chronological role of HA in CaP development. 
The primary research goal of this project was to evaluate the concerted effect of 
HAS and Hyal in prostate tumor biology, with particular emphasis on tumor growth, 
angiogenesis and metastasis. The eventual goal will be to identify novel molecular 
pathways underlying the phenotypic differences due to altered HA metabolism, thus 
charting the path for development of biomarkers for CaP diagnosis, and new targets for 
therapeutic strategies. 
 
1.9 APPROACH AND OVERVIEW OF CHAPTERS 2-4 
The first approach we took to address the hypothesis was to identify a suitable 
prostate tumor cell line, which expresses negligible or low levels of endogenous HAS and 
Hyal. Systematic screening of various available prostate cancer cell lines identified the 
non-metastatic 22Rv1 prostate cancer cell lines for our studies. We developed stable cell 
lines constitutively expressing the HAS2/3, Hyal1 and co-expressing HAS2/3 and Hyal1 
in the 22Rv1 cell lines. These cell lines were evaluated in vitro for the transgene 
expression, and for tumorigenic properties such as intrinsic growth rate and ECM 
adhesion. We additionally developed a tetracycline-inducible system to directly evaluate 
the correlation between HA production and tumor cell growth in vitro. Subsequently 
studies were done in subcutaneous mouse models to test the effect on tumor growth and 
angiogenesis (Chapter 2). Since, a true picture of tumorigenesis and metastasis of these 
transfectants can only be obtained in relevant prostate microenvironment, we tested these 
Hyal1/HAS transfectants in orthotopic prostate models. The transfectants were 
29 
characterized for the tumorigenic, angiogenic and metastatic properties in vivo and 
further to that we obtained a mechanistic correlation in vitro for tumor cell cycle 
progression (growth), adhesion and motility (metastasis) (Chapter 3). We further 
characterized growth factor mediated effects on ERK activation in cells expressing Hyal1 
and HAS3. We also carried out methodical characterization of the various cell cycle 
regulatory proteins to illuminate the underlying mechanism for altered cell cycle kinetics 
and tumorigenesis in the Hyal1 and HAS transfectants (Chapter 4). 
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CHAPTER 2 
 
INDUCIBLE HYALURONAN PRODUCTION REVEALS DIFFERENTIAL EFFECTS ON 
PROSTATE TUMOR CELL GROWTH AND TUMOR ANGIOGENESIS 
 
 
 
 
 
 
 
 
 
Note: This chapter has been published. The authors are Alamelu G. Bharadwaj, 
Katherine Rector and Melanie A. Simpson. The animal work presented in this chapter 
was carried out by Dr. Melanie A. Simpson. 
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2.1 ABSTRACT 
Prostate cancer progression can be predicted in human tumor biopsies by 
abundant hyaluronan (HA) and its processing enzyme, the hyaluronidase Hyal1. 
Accumulation of HA is dictated by the balance between expression levels of HA 
synthases, the enzymes that produce HA polymers, and hyaluronidases, which process 
polymers to oligosaccharides. Aggressive prostate tumor cells express 20-fold higher 
levels of the hyaluronan synthase HAS3, but the mechanistic relevance of this correlation 
has not been determined. We stably overexpressed HAS3 in prostate tumor cells. 
Adhesion to extracellular matrix and cellular growth kinetics in vitro were significantly 
reduced. Slow growth in culture was restored either by exogenous addition of 
hyaluronidase or by stable Hyal1 coexpression. Coexpression did not improve 
comparably slow growth in mice, however, suggesting excess hyaluronan production by 
HAS3 may alter the balance required for induced tumor growth. To address this, we used 
a tetracycline inducible HAS3 expression system in which hyaluronan production could 
be experimentally controlled. Adjusting temporal parameters of hyaluronan production 
directly affected growth rate of the cells. Relief from growth suppression in vitro but not 
in vivo by enzymatic removal of HA effectively uncouples the respective roles of 
hyaluronan in growth and angiogenesis, suggesting growth mediation is less critical to 
establishment of the tumor than early vascular development. Collectively, results also 
imply that HA processing by elevated Hyal1 expression in invasive prostate cancer is a 
requirement for progression. 
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2.2 INTRODUCTION 
Despite improved detection and diagnosis of prostate cancer, this disease remains 
the second leading cause of malignant mortality in U.S. males1,2. Metastasis may occur 
with no prior indication of an invasive tumor3, so prostate cancer progression is difficult 
to predict. Changes in levels of extracellular matrix molecules such as hyaluronan (HA), 
a high molecular weight polysaccharide, and its processing enzyme, the hyaluronidase 
Hyal1, within the prostate extracellular matrix have been correlated to invasive prostate 
cancer progression4-11. The molecular mechanisms underlying this correlation could 
provide important insights for therapeutic development or improved diagnosis of prostate 
cancer. 
HA production is a tightly regulated process that impacts cellular transformation 
and motility during development12-14. Dynamic HA turnover within tissues controls many 
acute processes such as wound healing or immune function. HA accumulation is the 
outcome of a balance between the activity of HA synthases (HAS), enzymes that 
synthesize the linear polymers15, and hyaluronidases, which process the polymers to 
biologically potent oligosaccharides16. Excess quantities of large HA polymers have been 
reported to suppress cellular growth17,18 and angiogenesis19,20, whereas processed 
oligosaccharides dramatically stimulate angiogenesis21-23 and fully degraded 
oligosaccharides induce apoptosis14,24,25. HAS isozymes (HAS1, HAS2 and HAS3) have 
been overexpressed in several tumorigenic cell lines, and may impact tumor growth 
kinetics in a dose dependent fashion26. For example, relatively low overexpression of 
HAS2 augments tumorigenesis, while high levels of HAS2 expression either have no 
effect or suppress growth of subcutaneous tumors. Interestingly, a similar effect was 
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recently shown for the hyaluronidase Hyal15, originally identified as a tumor suppressor27 
despite its subsequent direct correlation with cancer5,8,28. HA turnover is intricately 
orchestrated by the hyaluronidases Hyal1 and Hyal229-31, in conjunction with the HA 
receptor CD4432,33. Hyal1 is secreted and deposited to the extracellular space, where it 
may be retained non-covalently by binding to HA30. Hyal2 is GPI-anchored at the cell 
surface, localized to microdomains with CD4434, stimulation of which signals HA uptake 
subsequent to its initial extracellular processing by Hyal1/2. Hyal1 exhibits maximal 
activity at acidic pH, while Hyal2 is active in both acidic and neutral conditions, 
consistent with intracellular lysosomal function of both enzymes upon internalization35,36. 
However, presence of locally acidic microdomains at individual cell surfaces34 and within 
rapidly developing tumors37,38 may promote inappropriate activation, particularly of 
Hyal1, in the extracellular compartment. Differential hyaluronidase activity may thereby 
translate to a gradient of angiogenic and apoptotic oligosaccharides. The importance of a 
balance between expression levels of HA biosynthetic and processing enzymes for tumor 
cell growth is further suggested by the finding that HAS2 overexpression may promote 
growth in cell types with significant hyaluronidase activity, while it inhibits growth of 
cells lacking hyaluronidase39. 
We have previously shown that aggressive prostate tumor cell lines secrete excess 
HA and retain it at the cell surface in large matrices, a property that differentially 
mediates the interaction of the tumor cells with stromal and epithelial cell types40,41. 
Production of excess HA by prostate tumor cells is catalyzed by elevated levels of HAS2 
and HAS3, specifically in aggressive cells. Inhibition of HAS expression in these cells 
interferes with tumorigenesis, angiogenesis and metastasis, so the HA product clearly has 
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a role in these processes in a prostate tumor model41. When we coexpressed HAS2 and 
Hyal1 in stable tumor cell lines, resultant subcutaneous tumor sizes were 2-3-fold larger 
than those arising from either HAS2 or Hyal1 individually transfected cells42, suggesting 
combined production and processing of HA contribute synergistically to tumor growth 
mechanisms. 
Since HAS3 is the most dramatically upregulated isozyme in metastatic prostate 
tumor cells, we reasoned that its upregulated expression would have a demonstrable 
influence on HA matrix production and sought to test the functional relevance of this 
correlation. We report here the first overexpression of HAS3 in prostate tumor cells. 
Stable lines were selected for HAS3 overexpression or for Hyal1/HAS3 coexpression to 
assess the respective outcomes in mice. Since HAS3 overexpression suppressed 
tumorigenesis, we additionally developed a tetracycline inducible system for HAS3 
overexpression and directly evaluated the correlation between HA production and 
prostate tumor cell growth in vitro. Our findings support a model in which excess HA 
suppresses tumorigenesis by diminishing apparent cellular growth and limiting 
angiogenesis. Hyal1 is thus implicated in promotion of angiogenesis by dissipation of 
accumulated HA within tumors, which may facilitate its recognition as an angiogenic 
signal. 
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2.3 MATERIALS AND METHODS 
 
2.3.1 Cell Culture, Materials, and Reagents 
22Rv1 human prostate adenocarcinoma cells43 were purchased from ATCC and 
maintained in RPMI-1640 medium containing 10% fetal bovine serum. Selection, 
characterization and maintenance of 22Rv1 stable transfectants in standard medium 
containing 1.25 mg/ml G418 has been previously described42. The pIRES2-EGFP vector 
and plasmids pTet-ON and pTRE-Tight that comprise the tetracycline-inducible 
mammalian expression system were obtained from Clontech (Mountain View, CA). 
Doxycycline and Tet System approved fetal bovine serum were also from Clontech. Anti-
Flag antibody was purchased from Stratagene (La Jolla, CA). Collagens I and IV were 
from BD Biosciences (San Jose, CA). Fibronectin, laminin and calcein-AM were from 
Invitrogen (Carlsbad, CA) and antibodies to alpha and beta integrins were from 
Chemicon (Temecula, CA). Human umbilical cord HA, alcian blue and 
tetramethylbenzidine were from Sigma (St. Louis, MO). Streptomyces hyaluronidase was 
purchased from Calbiochem (EMD Biosciences, San Diego, CA). Biotinylated HA 
binding protein (bHABP) was from Seikagaku (Associates of Cape Cod, East Falmouth, 
MA). 
 
2.3.2 Transfection and Stable Selection of Prostate Tumor Cells 
The plasmid constructs encoding Flag epitope-tagged Hyal1 or HAS3 were 
previously described41,42. 22Rv1 human prostate tumor cells were transfected with: 1) 
vector alone (pIRES2-EGFP), 2) plasmid encoding Hyal1-Flag, 3) HAS3-Flag plasmid, 
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or 4) both the Hyal1 and the HAS3 plasmid constructs. Liposome-mediated transfection 
with FuGene6 reagent (Roche Diagnostics, Indianapolis, IN) was performed according to 
the manufacturer’s protocol. Gene expression was verified by western blot, and by 
enzyme activity assays as described. Stable 22Rv1 transfectants were obtained by clonal 
isolation following incubation for 14-20 days with G418 (1.25 mg/ml). Multiple clones 
were tested for expression and those with average levels of expression were pooled to 
eliminate the bias from isolated selection. Once established, stable transfectants were 
maintained in the selection medium. 
 
2.3.3 Western Analysis of Transgene Expression 
Conditioned media from cells cultured in 10 cm plates were prepared for western 
analysis by diluting 1:1 with SDS gel-loading buffer and boiling for 5 min. To prepare 
whole cell lysates, cultured cells were washed with PBS and lysed by addition of 0.5 ml 
of hot SDS gel-loading buffer. Cellular lysates were homogenized by shearing through a 
26-gauge needle, incubated at 37˚C for 20 min and centrifuged. All samples were 
normalized for protein content or cell number as indicated. Equal amounts of each sample 
were separated by SDS-PAGE and transferred to Immobilon-P membrane. After 
blocking, membranes were probed with anti-Flag M2 or anti-VP16 antibody as 
appropriate (2 μg/ml) and blotted proteins were detected by enhanced 
chemiluminescence. For densitometric analysis, samples loaded in triplicate were blotted. 
Western blots were scanned and converted to grayscale in Adobe Photoshop. Pixel 
density in identically sized regions encompassing each band was used to calculate the 
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mean ± SEM for expression levels in Hyal1/HAS3 cotransfectants relative to HAS3 
transfectants. 
 
2.3.4 Hyaluronidase Activity Assays 
Overnight conditioned media from stably transfected cell lines were concentrated 
ten-fold and electrophoresed by SDS-PAGE on a 12% polyacrylamide gel containing 0.2 
mg/ml HA. After a 1 h incubation at room temperature in 3% Triton X-100, the gel was 
placed in hyaluronidase assay buffer (50 mM sodium formate, pH 4.0, 150 mM NaCl, 
0.1% BSA) at 37˚C overnight. Hyaluronidase activity was detected as a clear band at the 
expected molecular weight for Hyal1 upon staining 1 h with 0.5% alcian blue and 
destaining with 7% acetic acid. Cell lysates were assayed similarly and although several 
light bands were visible, no significant differences were observed between control and 
Hyal1 transfected cells indicating the majority of overexpressed Hyal1 was secreted. 
To quantify hyaluronidase activity, we used a microplate assay essentially as previously 
described6. Briefly, serial dilutions of concentrated conditioned media normalized for 
protein content were applied in triplicate to HA-precoated microwell plates. Following a 
1 h incubation in hyaluronidase assay buffer, wells were washed and developed with 
biotinylated HABP, followed by avidin-biotin HRP with tetramethylbenzidine substrate. 
Absorbance at 650 nm was used to interpolate specific activity from a concurrent 
Streptomyces hyaluronidase standard curve. In competition assays, exogenous HA 
(average MW of ≈20 kDa, Lifecore, Chaska, MN) was included in the 1 h plate 
incubation. 
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2.3.5 HA Quantification 
HA content of transfected cell culture supernatants was determined by 
competitive binding assay6,44,45. Overnight conditioned media from prostate tumor cell 
cultures were harvested and cells counted. Equal volumes of serially diluted media were 
combined with biotinylated HABP (0.5 μg/ml), and incubated in HA-precoated microtiter 
plates for 6-8 h. Plates were developed using avidin-biotin HRP with 
tetramethylbenzidine as substrate, and absorbance was read at 650 nm. HA concentration 
was interpolated from a standard curve and normalized to cell number. 
 
2.3.6 HA Pericellular Detection and Quantification 
Pericellular HA retention was visualized and quantified by particle exclusion as 
described previously41,45. Briefly, cell cultures were incubated with 2 mg/ml aggrecan 
followed by addition of 1x108 fixed red blood cells. After 15 min, cells were viewed with 
phase-contrast microscopy and digitally photographed at 400x magnification. Matrix 
retention was quantified using Adobe Photoshop to calculate relative areas for matrices 
and cellular boundaries of individual cells. HA matrix thickness is presented as the ratio 
of matrix area to cell area for each transfectant or condition. 
 
2.3.7 Growth Assays 
Two-dimensional growth in culture was assayed as previously described45. 
Equivalent passages of each tumor cell line were plated at 5000 cells/well in 24-well 
plates. At 24-hour intervals, quadruplicate wells of each cell line were released with 
trypsin, neutralized, and manually counted in a hemacytometer. Duplicate counts for each 
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well were averaged to obtain the total cell count per well. Each point is the mean ± SEM 
of the total cell counts. Though the graph presents data from a single assay in 
quadruplicate, the growth trends were reproduced in three additional identical assays. 
 
2.3.8 Mouse Subcutaneous Injection 
All mice were cared for and maintained under the supervision and guidelines of 
the University of Nebraska-Lincoln IACUC Committee. Male NOD/SCID mice (Jackson 
Labs) (8 animals per condition) were injected subcutaneously in each flank with 1x106 
tumor cells suspended in 100 μl of serum-free RPMI. After 28 days, mice were sacrificed 
and tumors were dissected and weighed. Mean tumor wet weight ±SEM was plotted for 
each cell line. Statistical significance was assigned by Student’s two-tailed t-test. The 
experiment was repeated with an additional 8 animals per cell line and similar results 
were obtained. 
 
2.3.9 Immunohistochemistry and Immunofluorescence 
HA content and vascularization of tumors were detected as described 
previously41. Briefly, after weighing, tumors were divided in halves. One half was 
formalin fixed and embedded in paraffin. The other half was snap frozen in OCT 
compound. For HA detection, paraffin-embedded tumors were sectioned, dewaxed, 
probed with biotinylated HABP and developed using the Vectastain ABC kit (Vector 
Laboratories, Irvine, CA). Sections were counterstained with Meyer’s hematoxylin to 
visualize cellular boundaries. White light images were collected at 200x magnification. 
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Vascularization of the tumors was assessed in ethanol fixed frozen sections (8 m 
thickness) by antibody staining for CD31 as described previously41,46. 
 
2.3.10 Angiogenesis Quantification 
CD31-phycoerythrin conjugated antibody staining of frozen sections was 
visualized by fluorescence microscopy. Five random sections from each of three tumors 
per cell line were digitally photographed with 5 s exposure time. Images saved as TIF 
files were converted from 16 bit to 8 bit in Adobe Photoshop, red channel fluorescence 
was isolated, images were converted to grayscale, inverted, and a black-and-white 
threshhold was arbitrarily set based on levels. The histogram function was used to 
determine vessel density as represented by density of black pixels at 0 on the black-to-
white scale. Average pixel density for each transfectant tumor section was normalized to 
the average pixel density for untransfected tumor sections. Statistical significance was 
assigned by Student’s two-tailed t-test. 
 
2.3.11 Extracellular Matrix Adhesion and Blocking 
Microplates were precoated with collagen I, collagen IV, laminin or fibronectin in 
serially diluted doses for 1 h at 37˚C and blocked with 3% BSA. Subconfluent cells were 
released with 1 mM EDTA, washed and resuspended in adhesion medium (serum-free 
RPMI 1640 containing 20 mM HEPES, pH 7.4, and 1% BSA), and labeled with calcein-
AM (25 µg/106 cells, 20 min at 37˚C). Labeled cells (104 cells/well) were incubated in 
quadruplicate wells of the precoated plates for 2 h at 37˚C. Non-adherent cells were 
removed with three gentle washes in adhesion medium. Remaining adherent cells were 
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lysed with 0.2N NaOH containing 1% SDS. Fluorescence was measured in a microplate 
spectrophotometer and the percentage of adherent cells relative to the input number was 
calculated from a standard curve of each labeled cell culture. For adhesion specificity 
tests, cells were preincubated with antibodies against integrins β1, α1, α2, or α5 (5 µg/ml) 
for 10 min at 37˚C prior to placing them in the substrate-coated microplates. Antibodies 
were present throughout the assay incubation. 
 
2.3.12 Generation and Characterization of Tet-inducible 22Rv1 Cells 
22Rv1 cells were transfected with pTet-ON using FuGene6 reagent and selected 
with 1.5 mg/ml G418 until isolated colonies were obtained. Individual colonies were 
amplified in the continuous presence of G418 and screened for expression of the 
tetracycline transactivator-VP16 fusion protein by western blots probed with anti-VP16 
antibody. VP16 positive clones were then tested for inducible gene expression by 
transient transfection with a GFP or luciferase reporter plasmid. Transfectants were 
induced by applying media containing 2 μg/ml doxycycline (dox) and digitally 
photographed or harvested to prepare soluble extracts 48 h later. To characterize HAS3 
expression, transient transfectants were initially induced with dox for 48 h, at which time 
conditioned media were assayed for HA content as described above and membrane 
enriched fractions were harvested by mechanical disruption and solubilization in 1% 
Triton X-100 for western blotting. In subsequent experiments, control and HAS3 
transient transfectants were induced with dox 24 h after transfection and plated (20,000 
cells/well) for simultaneous assays of growth rate, HA content and HAS3 expression as 
indicated in specific figures. In some experiments, exogenous Streptomyces 
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hyaluronidase (0.2 mU/ml final concentration per dose) was added daily throughout the 
time course. To assay the temporal effects of HA induction, transfectants (20,000 
cells/well) were plated and induced identically but dox was removed after day 4. At that 
time, all media were removed and replaced with fresh media. In additional experiments, 
cells were identically plated and assayed, but dox was not added until day 4, at which 
point all standard media were removed and replaced. 
 
2.4 RESULTS 
 
2.4.1 Stable Expression of HAS3 and Hyal1 
We previously characterized HAS and hyaluronidase isozyme expression and 
activity in 22Rv1 cells42. HAS3 was expressed at basal levels comparable to normal 
prostate and synthesized relatively little HA. Though RT-PCR indicated expression of 
Hyal1 message, its enzymatic activity was very low in comparison with that of Hyal1 
transfectants. Since our goal was to determine the respective and concerted functions of 
Hyal1 and HAS3, 22Rv1 cells were deemed an appropriate model in which to 
overexpress these enzymes. 
Stable lines were selected for overexpression of Flag epitope tagged Hyal1 or 
HAS3 from a constitutive eukaryotic promoter in the pIRES2-EGFP bicistronic reporter 
vector. Hyal1/HAS3 cotransfectants were identified that expressed approximately 
equivalent levels of Hyal1 with respect to the individual Hyal1 transfectants. Conditioned 
media from each transfectant were compared by western blot to the vector control (Figure 
2.1A) to verify similar expression levels. Corresponding activity of Hyal1 in the control 
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(lane 1), Hyal1 (lane 2), and Hyal1/HAS3 (lane 3) conditioned media was initially 
measured by HA substrate gel electrophoresis (Figure 2.1B). As expected, the control 
media contained very little hyaluronidase activity, while activity in the Hyal1 transfectant 
and cotransfectant media (lanes 2 and 3) was significantly increased. We then assayed 
serial dilutions of transfectant conditioned media in a quantitative microplate assay. 
Interestingly, though the specific activity of Hyal1 transfectant media was constant at all 
dilutions, the specific hyaluronidase activity of Hyal1/HAS3 media increased with 
dilution (Figure 2.1C). Thus, the Hyal1 activity in these cells was underestimated at the 
lower dilutions and its increasing specific activity implied the dilution of an inhibitor or a 
competitor. We postulated that HA produced in the media by concurrent expression of 
HAS3 could be competing with HA immobilized on the microplate and artificially 
reducing the apparent activity of Hyal1. To confirm this, we added two different 
concentrations of exogenous HA (MW ≈20kDa) to the Hyal1 microplate assays (Figure 
2.1D). At the endpoint, we measured the remaining HA content of the solution and 
plotted it as a fraction of exogenous HA added. Hyal1 activity was calculated from the 
amount of HA remaining on the plate and plotted as a fraction of the activity measured in 
the absence of exogenous HA (white bar). Though the enzyme is clearly active, 
degrading both solubilized and immobilized HA, its apparent activity in the microplate is 
significantly competed by inclusion of excess HA. These results are consistent with HA 
content of the Hyal1/HAS3 media reducing the measured Hyal1 specific activity. 
Nonetheless, using the 1:50 dilution data shown in Figure 1C we estimate that Hyal1 
activity of the Hyal1/HAS cells is only ≈1.75-fold higher than that of the Hyal1 cells. 
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Figure 2.1 Constitutive expression and activity of Hyal1. (A) Western blot of 
conditioned media from 22Rv1 cells stably selected for expression of control vector 
(GFP, lane 1), Hyal1 alone (lane 2), or Hyal1 and HAS3 concurrently (lane 3) probed 
with anti-Flag M2 antibody. Hyal1 was detected as a single band of ≈60 kDa. (B) Hyal1 
activity of GFP, Hyal1, and Hyal1/HAS3 stable transfectants was assayed by HA 
substrate gel. Concentrated conditioned media were normalized to cell number and 
electrophoresed in a HA-containing polyacrylamide gel. After an overnight incubation, 
areas of Hyal1 activity were revealed as clear bands upon staining with alcian blue and 
destaining with acetic acid. (C) Hyal1 activity of transfectant conditioned media was 
quantified by microplate assay and compared in serial dilutions. The mean ± SEM of 
triplicate determinations is plotted in mU/ml/mg protein. * p<0.01 relative to the 1:5 
dilution values (white bar). (D) Hyal1 activity was assayed by microplate in the presence 
or absence of exogenous ≈20kDa HA in the indicated amounts. Fraction of input HA 
degraded is indicated (left bars). * p<0.01 relative to HA 0 mg/ml (white bar). 
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Since HA is synthesized at the plasma membrane and concurrently secreted to the 
extracellular space, HAS3 activity was verified in the stable lines by quantifying HA in 
conditioned media and at the cell surface. Stable HAS3 transfectants produced > 30-fold 
more HA than control GFP or Hyal1 transfected cells (Figure 2.2A). Hyal1/HAS3 
cotransfectant media contained ≈ 9-fold more HA than controls. Expression levels of 
HAS3 were compared by western blot of whole cell lysates probed for the Flag epitope 
(Figure 2.2A, inset). Triplicate determinations of each of the three lysates showed that the 
Hyal1/HAS3 cotransfectants (representative sample in lane 3) expressed 69±3.1% of the 
HAS3-Flag quantity detected in single HAS3 transfectants (lane 2). Thus, the HA content 
of Hyal1/HAS3 cultures was only 30% of the HAS3 culture HA content, less than half of 
what would be expected from the comparable HAS3 protein level. This result suggests 
Hyal1, present in the media of the cotransfected cells, either processes HA as it is 
synthesized or facilitates its removal from the media. Particle exclusion analysis of 
surface HA showed significant HA retention by the HAS3 transfected cells (Figure 2.2C). 
Hyal1/HAS3 cotransfectants retained additional HA relative to GFP transfected controls 
(compare Figure 2.2, panels D and B, respectively). Matrix and cell boundaries were 
traced in digital images to quantify average cellular HA retention (Figure 2.2E). Results 
are consistent with HA accumulation in the media. Collectively, these data confirm both 
HAS3 and Hyal1 activities are significant in cotransfectants. 
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Figure 2.2 Expression and activity of HAS3 in stable transfectants. (A) Stable 
transfectants of 22Rv1 cells were compared for expression and activity of HAS3 by 
western blot and quantification of secreted HA. The inset panel shows a western blot of 
lysates from control GFP (lane 1), HAS3 transfectants (lane 2) or Hyal1/HAS3 
cotransfectants (lane 3) probed with anti-Flag antibody. HA content of conditioned media 
was determined by competitive binding assay as described in Experimental Procedures. * 
p<0.01 relative to GFP. Cell surface retention of HA was evaluated by particle exclusion 
assay as described. Representative images from at least 20 individual cells of each type 
acquired at 400x magnification are shown: (B) control GFP; (C) HAS3; (D) 
Hyal1/HAS3. Inset panels illustrate GFP reporter fluorescence of the cells photographed. 
(E) Individual matrix and cellular boundaries were traced in Adobe Photoshop on the 
digital images and used to calculate respective areas. Thickness of pericellular HA is 
plotted as a matrix:cell area ratio. 
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2.4.2 HAS3 Decreases Subcutaneous Growth and Vascular Density of Prostate 
Tumor Xenografts 
To assay the effects of HAS3 and Hyal1 overexpression in prostate tumorigenesis, 
we injected stable 22Rv1 transfectants subcutaneously in flanks of NOD/SCID mice. 
Tumor growth was monitored over a period of 4 weeks, at which time mice were 
sacrificed and tumors were excised for analysis. Comparison of the mean tumor wet 
weight shows essentially identical growth of control and Hyal1 transfectants (Figure 
2.3A). However, both HAS3 and Hyal1/HAS3 transfectants yielded ≈ 40% smaller 
tumors than GFP controls. Since we previously found that Hyal1 overexpression 
increased angiogenesis within subcutaneous tumors, we analyzed all tumors for vessel 
density by staining tumor sections for CD31, a blood vessel endothelial cell surface 
marker (Figure 2.3B). As expected, Hyal1 transfectant tumors were approximately 2-fold 
more vascular than controls. Vessel density of HAS3 tumors was 62% of controls, 
consistent with the extent of reduction in tumor size. Although tumor size did not change 
appreciably between the HAS3 and Hyal1/HAS3 transfectant tumors, vascularization of 
the cotransfectants was not statistically different from controls. This result suggests 
Hyal1 expression may compensate for suppression of angiogenesis by HAS3. 
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Figure 2.3 Effect of constitutive HAS3 expression on subcutaneous growth and 
vascularization of prostate tumors in mice. Stable transfectants of 22Rv1 selected for 
constitutive expression of control GFP, Hyal1, HAS3, or Hyal1/HAS3 coexpression were 
injected subcutaneously (1x106 cells per injection) into flanks of male NOD/SCID mice. 
After 28 days, animals were sacrificed and tumors were excised, weighed and sectioned 
for analysis. (A) Tumor size is plotted as mean tumor wet weight ± SEM of 8 animals per 
group. Statistical values are indicated. (B) Vascular density of tumors was determined by 
digital analysis of anti-CD31 antibody staining in cryopreserved sections. Each value 
represents the mean ± SEM of 15 digital images from 3 tumors per group normalized to 
values in control tumors. (C-F) HA was detected in formalin-fixed tumor sections using 
biotinylated HABP, followed by streptavidin-HRP conjugate and diaminobenzidine 
precipitation. Cells were counterstained with hematoxylin. Representative sections from 
each tumor type photographed at 400x magnification are shown: (C) GFP; (D) Hyal1; (E) 
HAS3; (F) Hyal1+HAS3. 
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To determine if there was a correlation between HA levels and suppression of 
tumor growth, HA content of the tumors was determined histologically in formalin-fixed 
sections. Virtual absence of HA, visualized as a brown precipitate among the purple 
hematoxylin counterstained cells, was evident in control GFP and Hyal1 transfectant 
tumors (Figure 2.3, panels C and D). The tumors arising from HAS3 transfectants 
exhibited extensive accumulation of pericellular HA (Figure 2.3E). HA was detected 
throughout Hyal1/HAS3 cotransfectant tumor sections, though not localized entirely in 
the pericellular space (Figure 2.3F). Thus, significant HA deposition in the tumors 
correlated with suppression of tumor growth. Concurrent expression of Hyal1 was not 
sufficient to eliminate HA accumulation in these tumors. 
 
2.4.3 HAS3 Overexpression Diminishes Intrinsic Growth Rate and Adhesion to 
Extracellular Matrix 
To address the mechanisms of reduced tumor growth upon HAS3 overexpression, 
we first assayed growth kinetics of the stable transfectants in culture. Quadruplicate wells 
plated with equal numbers of cells in suspension were counted manually each day for 
seven days (Figure 2.4). Growth rate of HAS3 transfectants (filled circles) was >60% 
slower than that of controls (filled squares). Interestingly, cotransfectants expressing both 
Hyal1 and HAS3 (open circles) grew at identical rates to controls. Inclusion of exogenous 
HA in the culture media of control or cotransfected cells throughout the assay had no 
effects on growth (not shown). These observations are similar to previously reported 
growth kinetics of HAS2 transfected and cotransfected cells42. Thus, presence of 
hyaluronan in excess reduces growth rate specifically of cells that are synthesizing it. 
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Figure 2.4 Growth kinetics of stable transfectants in culture. Equal numbers of 22Rv1 
cells stably selected for constitutive expression of control GFP (squares), HAS3 (filled 
circles), or Hyal1+HAS3 (open circles) were plated in 24-well plates. Quadruplicate 
wells of each cell line were trypsin released and manually counted each day for 7 days. * 
p<0.01 for HAS3 values (filled circles) relative to GFP values (filled squares). 
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Many adherent cell types, including tumorigenic lines derived from epithelial 
cells (i.e.; 22Rv1), are dependent upon engagement of cell adhesion receptors for survival 
and growth47. Impairment of adhesion in anchorage dependent cells leads to anoikis48, 
and apparent reduction in growth kinetics. Since hyaluronan accumulation at the cell 
surface has the potential to influence cell surface interactions physically, we investigated 
anchorage dependence of our stable transfectants by assaying adhesion to extracellular 
matrix (ECM) proteins commonly found in basement membranes and connective tissue. 
Tumor cell suspensions were first incubated in 96-well plates coated with type IV 
collagen (Col IV) or fibronectin (FN). While Hyal1 alone did not alter adhesion to these 
substrates, HAS3 transfectants were 45% less adherent to Col IV and 90% less adherent 
to fibronectin relative to the GFP control cells (Figure 2.5A). Importantly, Hyal1/HAS3 
cotransfectants exhibited control adhesion levels. Reduced adhesion of HAS3 cells by 
>90% was observed when assayed on Type I collagen, the major component of 
subcutaneous connective tissue, and laminin (Figure 2.5B, gray bars). Reduced adhesion 
was not due to retention of HA at the cell surface during the assays, because adhesion 
was not restored when exogenous hyaluronidase was included (Figure 2.5B, dark bars). 
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Figure 2.5 Adhesion to extracellular matrix proteins is compromised by stable 
HAS3 overexpression. Single cell suspensions were calcein labeled and incubated in 96-
well plates precoated with 5µg/ml of the indicated protein. Non-adherent cells were 
removed by gentle washing. Remaining adherent cells were lysed and fluorescence 
quantified in a microplate reader was normalized to a standard curve of labeled cells. (A) 
HAS3 transfectants adhere poorly to type IV collagen (Col IV) and fibronectin (FN), 
relative to all other cell lines. * p<0.01 relative to GFP values. (B) HAS3 transfectants 
were preincubated in the absence (gray bars) or presence (dark bars) of Streptomyces 
hyaluronidase prior to adhesion assay on the indicated substrates (Col I, type I collagen; 
LM, laminin). (C and D) Cells were preincubated with integrin blocking antibodies 
(5mg/ml) prior to assaying adhesion to type IV collagen (C) or fibronectin (D). From left 
to right, cells were treated with media alone (marble bars), anti-β1 (black bars), anti-α1 
(white bars), anti-α2 (light gray), or anti-α5 (dark gray). * p<0.01 relative to media alone. 
 
 
88 
Adhesion to ECM proteins and subsequent engagement of survival mechanisms is 
mediated at the cell surface by heterodimeric integrin receptors47-49. Each integrin 
consists of an α and a β subunit, both of which combine to form an extracellular ligand-
binding domain, with well characterized specificity for various ECM proteins. A single 
transmembrane sequence anchors these receptors at the cell surface and an intracellular 
signaling domain modulates cellular responses to ligand binding. We used function 
blocking antibodies to implicate specific integrins in the differential adhesion we 
observed. Adhesion to all four substrates was abolished by treatment with anti-β1 
antibodies (Figures 2.5C, 2.5D and data not shown). Inhibition of α1 and α2 integrins 
accounted for ≈70% of control cell adhesion to type IV collagen (Figure 2.5C), consistent 
with cell surface expression of these receptors in 22Rv1 cells and with the previously 
reported ligand specificity of the α1β1 and α2β1 integrin heterodimers. Dependence of 
adhesion on α2 integrin was no longer observed for the HAS3 transfectants. The limited 
adhesion of these cells was mediated completely by α1β1 integrin. Similarly, despite 
rather low expression of α5 integrin on the cell surface of any of the transfectants (not 
shown), adhesion of control, Hyal1, and HAS3 cells to the known α5β1 ligand, 
fibronectin, was almost completely inhibited with anti-α5 blocking antibodies (Figure 
2.5D). Hyal1/HAS3 transfectant adhesion to fibronectin was only inhibited by ≈15% with 
these antibodies, possibly suggesting integrin use or activation state is altered in these 
cells. Collectively, results are consistent with compromised cell adhesion by HAS 
overexpression as an underlying cause of reduced tumor cell growth in vitro and in vivo. 
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2.4.4 Development and Characterization of Inducible 22Rv1 Cells 
To investigate the relationship between excess HA production and cellular growth 
phenotype, we established an inducible expression system. Three 22Rv1 clones were 
selected for stable expression of the VP16 tetracycline (tet) transactivator protein that 
confers tet-dependent transcription (Tet-ON #1,2,3). Of these, 22Rv1 Tet-ON#1 
expressed the highest levels of the transactivator and was characterized for inducible gene 
expression by transient transfection with constructs encoding GFP or HAS3 (Figure 2.6). 
The four-panel series shows results of GFP transient transfection. Bright field images 
illustrated comparable confluency of cultures in the absence and presence of the tet 
analog doxycycline (dox, Figure 2.6, panels A and B). Minimal GFP fluorescence was 
observed in the absence of dox induction (Figure 2.6C) and dramatic GFP fluorescence 
was induced by addition of dox to the culture medium (Figure 2.6D). 
Similar transfections were performed to evaluate specific induction of HAS3 
expression and HA production. Parental 22Rv1 cells and inducible 22Rv1 Tet-ON cells 
were transiently transfected with tet-responsive GFP or HAS3 constructs as indicated 
(Figure 2.6E). Cells were incubated in the presence (+) or absence (-) of dox prior to 
collecting conditioned media and cell lysates. In the inset panel, lysates from 22Rv1 Tet-
ON transfectants were analyzed by western blot probed with anti-Flag antibody. Robust 
induction of HAS3 was observed with respect to control GFP and uninduced HAS3 
transfectants. Some leakiness in expression was observed, as the HAS3 band was also 
faintly visible in the uninduced lysates. 
90 
 
Figure 2.6 Characterization of inducible 22Rv1 cells. 22Rv1 Tet-ON cells were 
transiently transfected with constructs encoding GFP or HAS3 under the control of a Tet 
sensitive promoter. Bright field images of inducible GFP transfectants in the absence (A) 
or presence (B) of 2 g/ml dox were photographed at 200x magnification. Induction of 
GFP expression was visualized by fluorescence microscopy in the absence (C) or 
presence (D) of dox. (E) HAS3 protein induction was verified by western blots of whole 
cell lysates probed with anti-Flag. Resultant HA production by transiently transfected 
22Rv1 cells (left set of bars) in the absence (white bars) or presence (black bars) of dox 
was compared to HA production by similar transfectants of the 22Rv1 Tet-ON cell line 
(bars on right). * p<0.01 relative to GFP transfectants. ** p<0.01 relative to uninduced 
HAS3. 
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HA content of the media correlated well with expression levels of HAS3 protein. 
As expected, the inducible construct did not confer HA synthesis to the parental 22Rv1 
cells that lack the tet transactivator protein. Transfection of 22Rv1 Tet-ON with the 
inducible GFP construct also did not stimulate HA production. A significant amount of 
HA was produced by the uninduced HAS3 cells, consistent with HAS3 protein 
expression, but dox incubation induced HA production by an additional 4-fold. 
 
2.4.5 Induced HA Synthesis Impairs Cell Growth but can be Compensated with 
Exogenous Hyaluronidase 
We evaluated growth of the 22Rv1 inducible cells as described above for the 
stable transfectants (Figure 2.7A). 22Rv1 Tet-ON cells were transiently transfected with 
inducible constructs for GFP (squares) or HAS3 (circles). Cells were plated in the 
absence (open symbols) or presence (filled symbols) of dox. Induction of the GFP control 
did not impact growth. HAS3 transfection reduced growth somewhat even in the absence 
of dox, since the uninduced cells still produced significant amounts of HA. However, 
induction of HAS3 further impaired growth of the cells to a total of ≈ 50% overall. 
Considering the transfection efficiency of the cells was also about 50%, these 
measurements probably underestimated the full suppressive effect of HAS3 
overexpression. Importantly, adhesion to fibronectin and type IV collagen was not altered 
by HAS3 induction (data not shown), suggesting changes in integrin-mediated adhesion 
are a stable adaptation to long term elevated HA synthesis. 
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Figure 2.7 Growth kinetics of inducible transfectants in culture. (A) Equal numbers 
of 22Rv1 Tet-ON cells transiently transfected with inducible GFP (squares) or HAS3 
(circles) constructs were plated in quadruplicate in the absence (filled symbols) or 
presence (open symbols) of 2 µg/ml dox. * p<0.01 for HAS3 uninduced transfectants 
relative to uninduced GFP and for HAS3 induced relative to HAS3 uninduced. (B) 
Growth of inducible HAS3 transfectants was similarly assayed in the absence (white 
bars) or presence (gray and black bars) of dox. The effect of enzymatic HA removal by 
exogenously added hyaluronidase was compared by assaying growth of the induced 
transfectants in the absence (gray bars) or presence (black bars) of 0.1 U/ml of 
Streptomyces hyaluronidase added at day 3. * p<0.01 relative to induced, untreated (gray 
bars vs. black bars). (Inset) HA content of cell culture conditioned media from the assay 
was quantified by competitive binding assay at the days indicated. 
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Stable Hyal1/HAS3 cotransfectants exhibited normal growth, so we tested the 
cells induced for HAS3 expression to determine whether exogenously added 
hyaluronidase could restore growth kinetics. 22Rv1 Tet-ON cells transiently transfected 
with the inducible HAS3 construct were plated in the absence (Figure 2.7B, white bars) 
or presence (2.7B, gray and black bars) of dox. By day 2, growth of induced cells was 
reduced by ≈30%. Black bars illustrate growth of HAS3-induced cells with daily addition 
of Streptomyces hyaluronidase (0.2 mU/ml) to the culture medium starting at day 3. 
Impaired cell growth, reduced by 45% as of day 7 in the untreated induced cells (gray 
bars), was fully relieved by supplementation with hyaluronidase throughout the assay 
(black bars). To correlate this observation with HA production by the cells, HA content 
of the media was measured on the indicated days throughout the growth assay (Figure 
2.7B, inset panel). HA content of the growth-impaired HAS3-induced cell media (gray 
bars) was elevated ≈2-fold at day 2 and ≈10-fold at day 6 relative to the uninduced media 
(white bars). HA content of media from hyaluronidase treated cells decreased (following 
hyaluronidase addition at day 3, black bars) in inverse correlation to the increase in cell 
growth. 
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2.4.6 Temporal Control of HA Production Directly Influences Growth Kinetics of 
Tumor Cells 
The inducible system afforded us the advantage of being able to control the 
temporal expression of HAS3 and correlate resultant HA production with growth curves. 
22Rv1 Tet-ON cells transfected with the inducible HAS3 construct were plated in the 
absence (Figure 2.8A, white bars) or presence (gray and black bars) of dox. Inhibited cell 
growth in the dox induced groups was evident (≈43%) by day 4 (arrowhead). At this 
time, all cell culture media were replaced: cells represented by white bars were again 
given standard culture media and gray bar wells received dox-containing media. Black 
bars represent cells from which dox-containing media were removed and replaced with 
standard media at day 4. Removal of induction conditions restored growth rate of the 
latter group by day 8. Levels of HA measured in the conditioned media from each group 
of cells showed an expected drop due to media replacement at day 4, but whereas the 
induced cells began replacing HA (Figure 2.8B, gray bars), induced cells from which dox 
was removed (black bars) did not resynthesize HA. It should be noted that the magnitude 
of HA induction was lower when cells were induced at day 4, relative to day 0, probably 
resulting from expected plasmid copy number decrease following transient transfection. 
It is also apparent that relatively low amounts of HA synthesis (e.g.; ≈3-fold induced in 
the day 4 group) translated to a 31% decrease in cell count by day 6. These results are 
consistent with a direct correlation between elevated HA production and growth 
inhibition, and demonstrate that this inhibition is rapidly relieved by cessation of HA 
synthesis. 
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Finally, we plated 22Rv1 Tet-ON HAS3 transfectants in the absence (Figure 
2.8C, white and black bars) or presence (gray bars) of dox. Growth impairment in the 
induced group was again evident by day 4 (arrowhead), at which time culture media were 
again replaced. In this experiment, cells represented by the black bars were given dox-
containing medium to induce HAS3 expression at day 4. Whereas these cells had 
exhibited an identical growth rate to the uninduced controls up to day 4, cellular growth 
was significantly slowed by day 6 (p<0.05 for day 6 and day 8). HA levels in the culture 
media at each time point again reflected a direct relationship between HA production and 
growth suppression (Figure 2.8D). Collectively, the results of this work indicate that 
levels of HA produced by HAS3 overexpression in prostate tumor cells are anti-
angiogenic and anti-proliferative in subcutaneous tumors. Furthermore, removal of 
accumulated HA, either by enzymatic degradation through hyaluronidase or reduction of 
HAS3 expression, correlates directly to increases in tumor cell growth. 
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Figure 2.8 Temporal effects of HAS3 induction on cell growth. 22Rv1 Tet-ON cells 
transiently transfected with the inducible HAS3 construct were assayed for growth in the 
continuous absence (white bars) or presence (gray bars) of dox (A and C). HA content of 
conditioned media was determined at each corresponding time point (B and D). In panel 
(A), dox-containing media were removed and replaced with standard culture media 
(black bars). * p<0.01 for removed induction at day 4 (black bars) vs. continuously 
induced (gray bars). Color schemes used in the corresponding plot of HA content are the 
same (B). In panel (C), uninduced cells were given dox at day 4 (black bars). * p<0.01 
for day 4 induced (black) vs. continuously uninduced (white bars). (D) HA content of day 
4 induced cells is shown. 
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2.5 DISCUSSION 
Accumulation of HA and immunohistochemical detection of Hyal1 in human 
prostate tumor specimens is predictive of cancer recurrence following therapeutic 
intervention4,8. In prostate tumor cell lines, aggressive potential of the cells correlates 
with 20-fold excess HAS3, but the relevance of this correlation has not been determined. 
We stably overexpressed HAS3 in prostate tumor cells and found that the resultant excess 
HA production by the cells suppressed tumorigenesis, in part by retarding intrinsic 
growth. Excess synthesis of HA led to changes in integrin-mediated cell adhesion that 
may translate to tumor cell anoikis in the collagen-rich subcutaneous environment, but 
probably also inhibit tumor cell cycle progression. Coexpression of Hyal1 restored 
adhesion and growth in culture, but Hyal1 activity was insufficient to clear the 
accumulated HA in vivo. Thus, although Hyal1/HAS3 cotransfectant tumors were 
vascularized comparably to control tumors, HA polymers persisting within the tumors 
continued to suppress tumor cell proliferation. Use of an inducible expression system 
allowed us to determine an inverse correlation between tumor cell HA synthesis and 
growth kinetics that was independent of effects on cell adhesion, thereby implicating an 
additional HA receptor-mediated pathway for inhibition of cell cycle progression. 
Collectively, the data support a role for HA in initiating changes in cell surface receptor 
engagement that may be amplified and exploited subsequently in tumor promotion upon 
local HA dispersion. Therefore, HA processing by elevated Hyal1 expression in invasive 
prostate cancer is likely required for progression. 
The normal functions of HA are extremely diverse, despite its chemical simplicity 
(reviewed in14,25). HA is a linear anionic polymer comprised of a single repeating 
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disaccharide motif, critical for regulating cell division, cell motility and cellular 
transformation during development13,50-56. HA polymers and HA oligosaccharides have 
been implicated in distinct aspects of these processes. Responses to HA are mediated by 
cell surface receptors that cluster when bound to the multivalent HA polymers, and 
disperse when not bound, differentially triggering intracellular signals. For example, HA 
polymers stabilize focal adhesion contacts by clustering specific cell surface receptors 
that modulate cytoskeletal linker protein function18,57. Subsequently engaged signal 
transduction pathways halt cell cycle progression and inhibit cell motility. Polymers 
thereby preserve cell-free space in vivo by limiting proliferation and preventing 
endothelial infiltration for angiogenesis. Disruption of the HA polymer/receptor 
interaction by clearance of the polymers, or by competition of receptor binding with HA 
oligosaccharides24,25,58-60, correspondingly may stimulate proliferation, motility, and 
angiogenesis. Depending upon the size of the oligosaccharides, cells may also undergo 
apoptosis, anoikis or autophagy. Thus, it is important for overall tissue homeostasis that 
HA production and processing are tightly controlled. 
Consequences of excess HA production have been previously investigated by 
manipulation of HAS enzyme expression in several cell types. Mammary carcinoma61, 
fibrosarcoma62, or melanoma cells63 that overexpress HAS1 or HAS2 are more 
tumorigenic and/or metastatic in mice. Conversely, inhibition of HAS2 or HAS3 
decreases HA production and reduces tumorigenic potential of the cells45,64. Some 
controversy exists about potential differences in the HA polymers produced by different 
HAS isozymes. However, there is considerable overlap of the ranges of polymer sizes 
obtained, and no chemical or kinetic evidence for intrinsic differences in HA production 
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among the isozymes. This suggests differential effects of HA polymers are largely 
dependent on quantity, which is dictated primarily by HAS expression levels. 
The effect of HA on tumorigenesis was recently found by Itano, et al., to be 
concentration dependent26. Stable transformed fibroblast lines selected for different levels 
of HA production by HAS1 overexpression were proportionally more tumorigenic when 
synthesizing moderate amounts of HA, but tumor growth was inhibited somewhat in cells 
that produced excessive quantities. This result helps explain the anomaly in our findings 
that HAS3 is anti-angiogenic and anti-proliferative in prostate tumorigenesis. HAS3 was 
previously overexpressed in TSU cells, formerly thought to be of prostate origin but 
reclassified as bladder-derived65, and found to enhance tumorigenesis and metastasis66. 
However, levels of HA were not measured with respect to cell culture concentrations so it 
is not possible to determine whether quantities fell into the tumorigenic range of the 
curve determined by Itano, et al. Hyaluronidase expression was also not characterized in 
these cells and may have played a role in relief from HA suppression of growth. Of note, 
HA quantities produced by both HAS3 and Hyal1/HAS3 transfected cells in the current 
study exceeded the levels shown to suppress tumor growth. 
Achieving temporal control of HA production with the HAS3 inducible system 
afforded an opportunity to directly link the effects of differential HA levels on tumor 
growth in a constant cellular background. An additional observation was made possible 
by the comparison of stable lines selected for long term constitutive overexpression of 
HAS3 with those transiently induced to overexpress HAS3. Suppression of cell growth 
was observed in both conditions but adhesion to ECM proteins was only inhibited when 
HA overproduction was constitutive and stable. Disruption of cell-ECM interactions by 
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altered integrin function has been associated extensively with cell death by anoikis48,67,68. 
However, specific integrins (α1β1, α5β1 and αvβ3) have been shown to interact with the 
adaptor protein Shc to stimulate an alternative pathway for cell cycle progression67,69. We 
used integrin blocking antibodies to define the contribution of specific integrins to the 
residual adhesion of HAS3 transfectants to type IV collagen and fibronectin. Despite the 
dependence of control and Hyal1/HAS3 cotransfected cells on multiple integrins for 
binding to both collagen and fibronectin, HAS3 transfectants were completely dependent 
on α1β1 and α5β1, respectively. However, significantly reduced adhesion to these 
substrates implies correspondingly diminished receptor function. Thus, this may translate 
to a failure of HAS3 transfectants to stimulate cell cycling, as well as cell survival, in 
response to ECM proteins in vitro and in vivo. 
In contrast, the inducible HAS3 transfectants adhered comparably to all ECM 
substrates relative to controls. Thus, they are unlikely to be experiencing changes in 
integrin-mediated survival or cell cycle entry that would account for their decreased 
growth kinetics. Rather, these cells showed growth suppression only with sustained HA 
synthesis and accumulation in the conditioned media. Thus, it is likely that HA retention 
at the surface of the tumor cells themselves is transducing the signal for growth 
suppression. Previous reports of HA-induced cell cycle arrest have implicated the 
transmembrane HA receptor CD4418,57,70,71 as the critical cell surface signaling contact. 
CD44 promotes cell cycle progression in the absence of HA polymer ligation through 
differential association with cytoskeletal linker proteins such as ezrin18,57. Presence of HA 
polymers elevates a tumor suppressor protein, merlin, which binds the CD44 intracellular 
signaling domain, precluding direct association of CD44 and ezrin. In fact, ezrin was 
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recently investigated as a cancer progression marker and though the role in progression 
was inconclusive, both ezrin and merlin were found to be expressed in prostate tumor 
cells72. Thus, reduced cell growth by HAS3 overexpression may result from direct HA 
suppression of cell cycling through CD44/merlin, in addition to cell cycle arrest by 
altered integrin function. 
During normal cellular HA turnover, high molecular mass HA polymers are 
processed to relatively short polymers and/or oligosaccharides by hyaluronidase-
catalyzed hydrolysis16. Initial extracellular processing of HA to short polymers was 
recently demonstrated in cultured cells, dependent upon the expression of Hyal2. Cellular 
uptake of HA was subsequently found to require Hyal1, and was augmented by CD44. 
The authors proposed that extracellular Hyal1 bound HA and mediated its association 
with Hyal2 and CD44 at the membrane, where Hyal2 initiated hydrolysis. Once inside 
the cell, HA-Hyal1 complexes were ultimately localized to lysosomes, where the low pH 
activated Hyal1 for complete cleavage of HA to tetrasaccharides. Apparent activity of 
Hyal2 has also been shown to be enhanced by association in lipid rafts with CD44 and a 
Na+/H+ antiporter that locally acidifies membrane microdomains34. Thus, although 
Hyal1 has been shown to have optimal hyaluronidase activity at acidic pH, it is possible 
through HA-mediated complex formation within these acidic membrane domains, both 
Hyal1 and Hyal2 may be contributing to extracellular HA processing. Particularly in the 
context of acidic regions within tumor micro- environments, excessive presence of either 
Hyal1 or Hyal2 could be expected to yield excesses of extracellular HA degradation 
products that would normally be confined within the cell. The outcome could range from 
cell transformation to angiogenesis. 
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In fact, Hyal1 and Hyal2 have both been implicated in cancer progression. Hyal2 
is found elevated in conjunction with HAS2 and CD44 in invasive breast cancer73. Hyal1 
is correlated with aggressive cancer progression because its expression in human prostate 
tumor tissue samples predicts poor patient outcome8. Overexpression of Hyal1 in PC3M, 
a metastatic prostate tumor cell line, modestly increased lymph node positivity in an 
orthotopic model74. We have also determined that constitutive overexpression of Hyal1 in 
22Rv1 cells, which are normally non-metastatic, induces metastasis to paraaortic nodes 
upon orthotopic injection, though there was no effect on growth at the primary site28. 
Hyal1 may be required to release tumor cells from cell cycle and motility suppression 
imposed by HA-rich primary tumor tissues. HAS3 overexpression correlates with 
metastatic phenotype in multiple lineage derived tumor cell lines such as prostate and 
colon75. Hyal1 expression may rise in tumor tissues subsequently to HAS overexpression 
as a selected compensatory mechanism for growth suppression. Our finding that 
exogenous hyaluronidase can relieve growth suppression in vitro further implies that the 
source of the hyaluronidase in vivo can be exogenous, perhaps secreted by tumor-
associated stromal cells or macrophages. 
Constitutive HAS3 expression suppressed subcutaneous tumor growth and 
angiogenesis, which was not compensated by Hyal1 coexpression, despite the restored 
growth of cotransfectants in vitro. One possible explanation for this observation is that 
Hyal1 activity may be antagonized by endogenous hyaluronidase inhibitors76. This effect 
was not observed in our previous studies of Hyal1/HAS2 cotransfectants, however, 
suggesting rather that Hyal1 levels are insufficient to compensate for the increased HA 
production by HAS3 (about 5-fold higher than HA production by HAS242). 
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Hyaluronidases have been shown to be inhibited by excess HA polymer concentrations in 
vitro77, so this may also be the case in vivo, particularly depending on local fluctuations 
in tumor pH. Consistent with this notion, in our initial experiments with exogenous 
hyaluronidase addition to HAS3-induced tumor cells, we found that daily augmentation 
of hyaluronidase was essential to observe the effects of restored cell growth. In addition, 
measurements of Hyal1 activity in our assays of culture conditioned media (Figure 2.1C) 
showed submaximal specific activity until significantly diluted. Furthermore, significant 
HA accumulation was detected in tumor sections, suggesting that although Hyal1 
expression ameliorates growth suppression in culture, its ability to do so in vivo requires 
HA diffusion to relieve inhibition. Diffusion of HA may be more constrained in a three-
dimensional tissue context. 
Tumor size is a function of apparent tumor cell growth kinetics, whereas 
vascularization of the tumor is a response to a tumor-provided signal or a tumor-induced 
environmental cue. The data we have provided in vitro have highlighted two pathways by 
which HAS3 overexpression could be expected to result in suppression of tumor cell 
proliferation. Excessive HA could utilize similar signaling mechanisms to suppress the 
recruitment and proliferation of endothelial cells required for angiogenesis of HAS3-
overexpressing tumors. Similar impairment of Hyal1/HAS3 transfectant tumor growth, 
however, occurred despite unsuppressed angiogenesis. This could be partially explained 
by ≈50% HA clearance of these tumors relative to the HAS3 tumors, but if restored cell 
cycle entry was solely responsible for vascular development, tumor cell proliferation in 
the HA deficient regions would also be expected. Thus, we propose that angiogenesis is 
the result of endothelial cell recruitment by a tumor cell product generated within those 
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regions. This recruitment signal could either be Hyal1-bound HA complexes, or could be 
partially hydrolyzed HA polymers/oligosaccharides, response to which would be 
mediated by endothelial CD44. Further experiments will be required to define aspects of 
this model. 
In summary, we have developed a useful system with which to fine tune levels of 
HA production and uncouple the temporal effects of HA on growth control versus 
tumorigenesis. The direct relation of HA production to suppression of tumor growth and 
angiogenesis resolves the question of whether the product of HAS is intrinsically 
tumorigenic. Our findings imply that concurrent HA production and adequate processing 
activity are a requirement for maximal tumorigenic potential. The establishment of a 
direct relationship between cell growth rate and HA production implies that sudden 
immediate changes in HA production can control tumor growth. Since HA levels 
influence tumorigenesis in a dose dependent fashion, the sudden complete removal of HA 
production may impair growth of an established tumor in the same way high levels 
suppressed growth. Thus, the inducible system will permit us to test the relationship 
between HA and maintenance of established tumors in the same way we have 
investigated its role in tumor formation. A further advantage of the system is the ability to 
control HA levels within the same cellular background, thus avoiding some of the pitfalls 
of clonal selection. It will be important to test this relationship in orthotopic 
tumorigenesis and metastasis. We are currently developing stable inducible lines to 
perform these studies. 
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CHAPTER 3 
 
SPONTANEOUS METASTASIS OF PROSTATE CANCER IS PROMOTED BY EXCESS 
HYALURONAN SYNTHESIS AND PROCESSING 
 
 
 
 
 
 
 
 
 
Note: The results in this chapter have been published. The authors are Alamelu G. 
Bharadwaj, Joy L. Kovar, Eileen Loughman, Christian Elowsky, Gregory G. Oakley and 
Melanie A. Simpson. The animal work described in this chapter were carried out by Joy 
L. Kovar and Dr. Melanie A. Simpson. 
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3.1 ABSTRACT 
Accumulation of extracellular hyaluronan (HA) and its processing enzyme, the 
hyaluronidase Hyal1, predicts invasive, metastatic progression of human prostate cancer. 
To dissect the roles of hyaluronan synthases (HAS) and Hyal1 in tumorigenesis and 
metastasis, we selected non-metastatic 22Rv1 prostate tumor cells that overexpress 
HAS2, HAS3, or Hyal1 individually, and compared to cotransfectants expressing Hyal1 
+ HAS2 or Hyal1 + HAS3. Cells expressing only HAS were less tumorigenic than vector 
control transfectants upon orthotopic injection in mice. In contrast, cells coexpressing 
Hyal1 + HAS2 or Hyal1 + HAS3 showed >6-fold and >2-fold increased tumorigenesis, 
respectively. Fluorescence and histologic quantification revealed spontaneous lymph 
node metastasis in all Hyal1 transfectant implanted mice, and node burden increased 
another 2-fold when Hyal1 and HAS were coexpressed. Cells only expressing HAS were 
not metastatic. Thus, excess HA synthesis and processing in concert accelerates 
acquisition of a metastatic phenotype by prostate tumor cells. Intratumoral vascularity did 
not correlate with tumor size or metastatic potential. Analysis of cell cycle progression 
revealed shortened doubling time of Hyal1 expressing cells. Adhesion and motility on 
extracellular matrix were diminished in HA overproducing cells. However, motility was 
increased 2-fold by Hyal1 expression and 4-6 fold by Hyal1/HAS coexpression, in close 
agreement with observed metastatic potential. This is the first comprehensive 
examination of these enzymes in the relevant microenvironment for prostate cancer. 
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3.2 INTRODUCTION 
Prostate tumors detected early are often managed effectively by surgical resection 
and/or hormone ablation therapy. However, a significant percentage of tumors resume 
growth in the absence of androgens1. The transformation from androgen dependent to 
androgen independent prostate cancer is incompletely understood, and such tumors are 
typically highly aggressive. Progression of human prostate cancer to invasive and/or 
metastatic growth is accompanied by significant deposition and accumulation of 
hyaluronan (HA) within the tumors. HA is a large secreted glycosaminoglycan polymer 
that normally functions in motility and cell transformation during development and 
wound healing2-5. Matrices rich in HA tend to be comparatively deficient in covalently 
cross-linked fibrous protein networks6, more gel-like and less organized, thus altering the 
normal architecture of the tissue matrix by increasing its permeability. This undermining 
of tissue structural integrity may be permissive to pathological cell proliferation and 
movement, particularly in cancer4. Furthermore, its role as an adhesion and migration 
substrate for cells in development may translate to enhanced metastatic potential of cells 
bearing surface associated HA. 
Many previous reports have documented the involvement of HA and its receptors 
in prostate cancer progression7-13. In human prostate cancer patients, high levels of HA 
correlated with locally invasive tumor growth and PSA recurrence, both independent 
indicators of negative prognosis7. Quantification of the HA processing hyaluronidase, 
Hyal1, was demonstrated to be predictive of continued disease progression following 
hormone ablation therapy11, which is normally effective in early stage prostate cancers. 
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Our previous research has differentially implicated HA synthase isozymes HAS2 
and HAS3, both of which produce HA polymers, in conjunction with Hyal1, which 
processes HA polymers to oligomers, in aspects of aggressive tumor progression14-19. In 
particular, excessive cellular HA retention and autocrine processing was predicted to 
promote metastasis. Among cultured human prostate tumor cell lines, elevated HA 
production was found specifically in aggressive, metastatic cells, in which HAS2 and 
HAS3 isozymes were upregulated ≈3-fold and ≈30-fold, respectively17. Suppression of 
HAS2 and/or HAS3 expression by stable antisense RNA reduced the synthesis and cell 
surface retention of HA18, and inhibited primary subcutaneous19 or intraprostatic 
growth20. Reduced primary tumor growth was associated with comparable apoptotic and 
proliferative fractions in culture and in tumors, but virtually no vascularization of tumors. 
These results implicate HA, and specifically HAS2 and HAS3, in tumor angiogenesis, as 
well as intrinsic growth rate modulation. Interestingly, exogenous HA addition to knock-
down cells upon injection restored subcutaneous tumor growth and angiogenesis, 
implying the existence of a tumor or stromal factor (i.e.; a hyaluronidase) that could 
modulate effects of HA in trans, with the same malignant outcome. We hypothesized that 
concerted action of these enzymes at elevated levels in prostate tumors would facilitate 
aggressive primary tumor growth by potentiating tumor cell proliferation and 
vascularization of tumors. 
To segregate the effects of HA synthesis by the HAS enzymes from HA turnover 
by Hyal1, we previously selected 22Rv1 prostate adenocarcinoma cells to stably 
overexpress Hyal1, HAS2, or HAS3, and to coexpress Hyal1+HAS2 or Hyal1+HAS3. 
Growth kinetics in culture and in subcutaneous murine tumors were compared14-16. HAS2 
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expressed alone or coexpressed with Hyal1 in 22Rv1 tumor cells increased subcutaneous 
growth and vascularization of tumors. In contrast, overexpression of HAS3, which 
conferred 20-fold higher HA production than GFP controls and 5-fold more than HAS2 
transfection, diminished subcutaneous tumor growth and vascularization. Since the 
subcutaneous microenvironment is already a site of abundant HA turnover, we reasoned 
that the physiologically relevant microenvironment of the prostate, normally a site of low 
HA production and turnover, might be impacted differently by tumor cells with these 
properties, in a manner more representative of the human disease. Therefore, the goal of 
this study was to define the respective roles of HA synthases and hyaluronidases for the 
first time in orthotopic growth and metastasis of prostate tumor cells, and identify the 
underlying cellular processes affected. 
 
3.3 MATERIALS AND METHODS 
 
3.3.1 Cell Culture and Reagents 
22Rv1 human prostate adenocarcinoma cells from ATCC were cultured in RPMI-
1640/10% FBS as recommended. Stable transfectants were maintained in standard media 
supplemented with 1.5 mg/ml G418. Biotinylated HA binding protein (HABP) was from 
Seikagaku. Anti-mouse CD31-phycoerythrin conjugate was from BD Biosciences 
Pharmingen. Collagen type IV was from Fisher Biosciences. Standard mouse chow and 
purified maintenance diet (AIN-93M) were obtained from Harlan Teklad (Madison, WI). 
IRDye® 800CW EGF was supplied by LI-COR Biosciences (Lincoln, NE). The 
Odyssey™ Infrared Imaging System was also provided by LI-COR Biosciences. 
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3.3.2 Orthotopic Injection 
Male NOD/SCID mice (Jackson Labs, Bar Harbor, ME) were cared for and 
maintained under the supervision and guidelines of the University of Nebraska-Lincoln 
Institutional Animal Care and Use Committee. Six-week-old mice were anesthetized with 
2% isoflurane and injected in the left lobe of the dorsal prostate with 1x105 22Rv1 
transfectant cells (7 mice per group) suspended in serum free medium. Tumor growth 
was tracked by optical imaging at 2, 4, and 6 weeks, each time three days following 
intravenous injection of 1 nmol IRDye 800CW EGF targeting agent. Control animals 
injected only once at the endpoint confirmed that no differences in tumor size occurred 
within animal groups as a result of longitudinal exposure to the agent. In addition, tumor 
weights and lymph node H/E staining were repeated with identical results in a second 
experiment using eight animals per group, in which imaging was not used. 
 
3.3.3 Near Infrared Imaging of Tumors and Lymph Nodes 
NIR fluorescence imaging in live animals was performed with a prototype small 
animal imager as previously described15. Images were acquired and analyzed with 
Wasabi software from Hamamatsu Photonics (Hamamatsu City, Japan) or Adobe 
Photoshop (Adobe Systems Inc., San Jose, CA). For longitudinal tracking, shaved 
anesthetized mice were imaged in a sealed, sterilized portable compartment, circulated 
with HEPA-filtered air. 
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3.3.4 Statistical Analysis of Animal Fluorescence Data 
Images analyzed in a longitudinal series for each mouse were normalized using 
the same look up table with a common minimum and maximum value. Signal-to-noise 
ratio (SNR) was calculated using the following formula: 
background meanof  deviation Standard
intensity background Mean  ‐  intensity tumor Maximum
    SNR =  
Regions of interest (ROI) with identical areas were quantified for total pixel and mean 
pixel values. The standard deviation of mean backgrounds was calculated using 3-5 
ROIs. Statistical variance among tumor wet weights and lymph node metastatic burden 
was calculated by one-way ANOVA comparing each group mean to the GFP control 
group. Group means were evaluated for significance at probability values of 0.05 and 
0.01. 
 
3.3.5 Immunohistochemistry and Immunofluorescence 
HA content and vascularization of tumors were detected as described 
previously16,19. Briefly, tumors were divided in halves. One half was formalin fixed and 
embedded in paraffin. The other half was snap frozen in OCT compound. For HA 
detection, paraffin-embedded tumors were sectioned, dewaxed, incubated with 3 μg/ml 
biotinylated HABP in PBS/1% BSA overnight at 4˚C, and developed using the 
Vectastain ABC kit (Vector Laboratories, Irvine, CA). Sections were counterstained with 
Meyer’s hematoxylin. White light images were collected at 200x magnification. 
Vascularization of the tumors was assessed in acetone fixed frozen sections (8 μm 
thickness) by antibody staining for CD31 as described previously14,16,19,21. 
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3.3.6 Angiogenesis Quantification 
CD31-phycoerythrin conjugated antibody staining of frozen sections was 
visualized by fluorescence microscopy. Ten random sections from each of three tumors 
per cell line were digitally photographed with 5 s exposure time, saved as TIF files, and 
processed. Average pixel density for each transfectant tumor section was normalized to 
the average pixel density for untransfected tumor sections. One-way ANOVA was used 
to determine if variance in total vascular pixel density among the 30 images for each 
transfectant tumor group was significantly different from 30 images of the GFP control 
transfectant tumors. Significance was evaluated at probabilities of 0.05 and 0.01. 
 
3.3.7 Cell Cycle Analysis 
Transfectant tumor cells cultured in standard medium were trypsinized, washed, 
fixed overnight at -20˚C, and stained overnight at 4˚C with propidium iodide containing 
RNase. Cells were analyzed by flow cytometry using a FACSArray Bioanalyzer (BD 
Biosciences) with ModFit Software. Percentages of each transfectant cell type in 
respective phases of the cycle were plotted (asynchronous). To synchronize cells, which 
were not susceptible to serum synchronization, we treated for 24 h with 0.2 mM 
nocodazole, a mitotic inhibitor. Treated cells were segregated into two pools, one of 
which was continually exposed to nocodazole (arrested) and one from which nocodazole 
was removed for 24 h prior to assay (arrested and released). Cells were analyzed 
similarly to the asynchronous population. Statistical significance at each time point was 
assessed by one-way ANOVA relative to GFP control values. 
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3.3.8 Extracellular Matrix Adhesion 
Microplates were precoated with type IV collagen in serially diluted doses for 1 h 
at 37˚C and blocked with 3% BSA. Subconfluent cells were released with 1mM EDTA, 
washed, resuspended in adhesion medium (serum-free RPMI 1640 containing 20 mM 
HEPES, pH 7.2, and 1% BSA), and labeled with calcein-AM (25 μg/106 cells, 20 min at 
37˚C). Labeled cells (104 cells/well) were incubated in quadruplicate wells of the 
precoated plates for 2 h at 37˚C. Non-adherent cells were removed with three gentle 
washes in adhesion medium. Remaining adherent cells were lysed; fluorescence was 
quantified and the percentage of adherent cells relative to the input number was 
calculated from a standard curve of each labeled cell culture. Significance was 
determined by one-way ANOVA. 
 
3.3.9 Motility 
Motility of the transfectants was assayed using a 48-well modified Boyden 
chamber (Neuroprobe, Inc., MD). Briefly, single cell suspensions (20,000 cells/well) in 
serum free RPMI were placed in quadruplicate into the upper wells of the chamber with 
type IV collagen (10 μg/ml) in the lower well. Membranes used to separate the wells 
were 8μM pore size. Following 20 h incubation at 37˚C in a humidified chamber, 
membranes were fixed and stained with Diff-Quik (Fisher Biosciences), and placed with 
migrated side down on a glass microscope slide. Non-migrated cells were wiped away 
with a cotton swab. Remaining migrated cells were counted at 150x magnification in five 
random fields per well and plotted as mean ± SEM of average migrated cells per well. 
Significance was determined by one-way ANOVA. 
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3.4 RESULTS 
 
3.4.1 Orthotopic Prostate Tumorigenesis is Enhanced by Coexpression of HA 
Synthesizing and HA Turnover Enzymes. 
To examine the role of HA metabolic enzymes in prostate tumorigenesis and 
metastasis, we performed orthotopic injections in male NOD/SCID mice. From the 
orthotopic site, we previously determined that 22Rv1 cells were non-metastatic but could 
be induced to metastasize to the para-aortic lymph nodes within a six-week time course 
upon overexpression of Hyal115. Growth of tumors was monitored over six weeks by near 
infrared optical imaging using fluorescent dye conjugated to EGF. At two-week intervals, 
images were collected and analyzed for total lower abdominal fluorescence at signal to 
noise ratios of >3 standard deviations above background (Fig 3.1A). Differential growth 
rates among the tumors were evident by week 2, with several consistent trends emerging 
by week 4. At six weeks, prostates were harvested and weighed (Fig 3.1B). As we 
observed previously, Hyal1 overexpression alone did not alter endpoint tumor size. Either 
HAS2 or HAS3 expression suppressed intraprostatic 22Rv1 growth, with only ≈25% 
(HAS2) and ≈58% (HAS3) of injected animals bearing tumors. Of the resulting tumors, 
the overexpression of either HAS2 or HAS3 also reduced tumor size, though statistical 
significance for HAS3 was not established (p=0.06). In contrast, concurrent expression of 
HAS2 and Hyal1 or HAS3 and Hyal1 increased tumorigenesis ≈6-fold and ≈2-fold, 
respectively. 
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Figure 3.1 Orthotopic prostate tumorigenesis is enhanced by coexpression of HA 
synthesizing and HA turnover enzymes. Single cell suspensions of transfected cell 
lines as indicated were injected in 10 μl of serum-free RPMI to the dorsal prostate of 
male NOD/SCID mice (7 per group, repeated in triplicate). (A) Tumor growth was 
monitored longitudinally at two-week intervals by NIR optical imaging. Mice were 
imaged 72 h after IV injection of IRDye 800CW EGF (1 nmol). Images were analyzed 
for total tumor fluorescence detected at signal to noise ratios of >5 standard deviations 
above background. (B) At six weeks post surgery, following the final image capture, 
animals were sacrificed and tumors were harvested and weighed. Plotted is the mean 
tumor wet weight ± SEM for all mice; * p<0.01. 
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Suppressed growth of HAS-overexpressing cells is consistent with previously 
characterized intrinsic growth rates of the respective cell lines in culture14,16. However, 
the increased tumorigenic potential of Hyal1+HAS coexpressing cells in the otherwise 
HA deficient prostatic environment exceeds the growth potential predicted by the 
intrinsic kinetics in culture, suggesting additional parameters are important for prostate 
colonization of the transfectants. 
HA content of prostate tumors was evaluated by probing paraffin-embedded 
sections with a specific HA binding protein (Figure 3.2). As expected, neither control 
GFP nor Hyal1 tumor sections stained appreciably for HA. However, the HAS2 and 
HAS3 tumors exhibited abundant HA accumulation at the cell surface and pooled within 
regions of the tumor matrix. Importantly, coexpression of either HAS isozyme with 
Hyal1 markedly reduced HA accumulation within the tumors. These observations are 
consistent with growth suppression by HA in high concentrations produced by HAS, and 
with relief from growth suppression upon Hyal1 mediated HA turnover. 
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Figure 3.2 HA content of orthotopic tumor sections. Formalin-fixed paraffin-
embedded tumors were sectioned and stained with biotinylated HABP, followed by 
detection with streptavidin-conjugated HRP and diaminobenzidine precipitation to 
visualize HA content. Sections were counterstained with hematoxylin and representative 
fields were digitally photographed at 200x magnification. 
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3.4.2 Enhanced Tumorigenesis in the Prostate does not Correlate with 
Intratumoral Blood Vessel Density 
One potential explanation for increased tumor growth could be that Hyal1-
catalyzed degradation of HA may occur in the extracellular space22, giving rise to low 
molecular weight HA oligosaccharides with angiogenic potential23, and thereby 
promoting vascularization of the tumors. Therefore, we quantified the vascular density of 
the tumor sections by probing with anti-CD31 (Figure 3.3 graph). In contrast to what we 
expected, vascularization of prostate tumors arising from each of the cell lines was 
modestly increased by HAS-mediated HA production but was unaltered by concurrent 
HA processing. Interestingly, scrutiny of the raw images for each tumor analyzed (upper 
panels of Figure 3.3) revealed a notable difference in the morphology of the intratumoral 
vessels. Tumors arising from HAS overexpressing cells contained vasculature of more 
robust appearance as judged by the intensity of fluorescence staining. They were also 
more sparsely distributed within the tumor. Vessels occurring within GFP control tumors 
and all Hyal1-expressing transfectant lines (Fig 3.3, right column panels) were 
significantly finer in appearance and were more numerous per unit area than in the HA 
rich tumors. 
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Figure 3.3 Enhanced tumorigenesis in the prostate does not correlate with 
intratumoral blood vessel density. Orthotopic tumors were embedded in OCT 
compound and cryosectioned. Sections were stained with anti-CD31-PE conjugate and 10 
randomly selected sections per tumor were digitally photographed under a fluorescence 
microscope at 400x magnification with 5s exposure time. Representative images from 
each tumor type as indicated are shown. Images were processed as indicated in Materials 
and Methods to obtain total vessel area per section as pixel density. Mean pixel density 
per section ± SEM is plotted for 10 sections of three different tumors per group; 
* p<0.01, ** p<0.05. 
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3.4.3 Spontaneous Lymph Node Metastasis is Initiated by Hyal1 and Potentiated 
by HAS/Hyal1 Coexpression 
Following tumor removal from the sacrificed mice, para-aortic lymph node 
metastases were visualized by near infrared optical imaging (Figure 3.4). Representative 
images of lymph nodes (LN) in situ were captured (Fig 3.4A) prior to excision of the 
nodes. Ex vivo images were then collected (Fig 3.4B, 3.4D) and used to quantify node 
fluorescence as a measure of metastatic burden in mice injected with each cell line. 
Results were confirmed by histological staining of sectioned nodes from each animal in 
the study (Fig 3.4C, 3.4E). Fluorescence intensity of the nodes was quantified and 
normalized to that of the nodes from the GFP control group (Fig 3.4F). As we previously 
found, overexpression of Hyal1 alone induced metastasis of non-metastatic 22Rv1 cells. 
However, coexpression of either HAS isozyme with Hyal1 significantly increased size 
and total fluorescence of lymph nodes by a further 2.3-fold (HAS2, p<0.01) or 1.7-fold 
(HAS3, p<0.01). Therefore, the combined expression of Hyal1 and HAS provides a 
synergistic stimulus for prostate tumor growth and metastasis. 
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Figure 3.4 Spontaneous lymph node metastasis is initiated by Hyal1 and potentiated 
by HAS/Hyal1 coexpression. Three days prior to study termination, mice were injected 
IV with IRDye 800CW EGF (1 nmol). After final image capture, animals were sacrificed 
and dissected to expose the para-aortic lymph nodes. (A) Images of lymph nodes in situ 
from representative animals are shown for comparison at the same look-up table. Excised 
lymph nodes from all animals in the study were imaged intact for fluorescence 
quantification (B, D) and sectioned for histology (C, E). Nodes shown are from animals 
injected with HAS2 (B, C) and Hyal1/HAS2 (D, E) transfectants. (F) Fluorescence 
intensity (800 channel signal with SNR>3) of all excised nodes was normalized to 
fluorescence of nodes from mice injected with control GFP transfectants. Mean ± SEM is 
plotted; * p<0.01. 
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3.4.4 Cell Cycle Analysis Reveals Accelerated Cell Cycling of Hyal1-
Overexpressing Cell 
To determine mechanisms underlying the observed changes in vivo, we 
investigated aggressive tumor correlate behaviors in vitro. We previously found that 
HAS3 stable overexpression induced changes in cell surface integrin levels that resulted 
in compromised adhesion of the cells to extracellular matrix proteins14. This is one 
mechanism by which HAS expression may suppress cell growth in the absence of 
sufficient hyaluronidase activity. Since impaired adhesion has the potential to impact 
apoptosis, cell cycle progression and cell motility, we examined these characteristics of 
the transfectants. Asynchronous populations of the transfectant cell lines were analyzed 
by propidium iodide staining and flow cytometry. Percentages of cells in each phase of 
the cell cycle, as well as the fraction of cells undergoing apoptosis, were quantified and 
compared for each cell line. Results were plotted for a representative assay (Figure 3.5A). 
The most striking points observed in these data were that cells overexpressing Hyal1 
alone exhibited an increase from ≈18% to ≈30% in S phase (DNA synthesis), while the 
G0/G1 (resting) phase fraction is similarly reduced. The intrinsic rate of Hyal1 
transfectant proliferation is ≈50% faster than GFP control transfected cells, which is 
consistent with a higher level of DNA synthesis and shorter overall doubling time. 
Concurrent expression of Hyal1 with HAS3 also significantly increased the fraction of S-
phase cells, consistent with restoration of their proliferative rates in culture and 
acceleration of tumor growth kinetics in vivo. Surprisingly, Hyal1/HAS2 coexpressing 
cells were not significantly different from controls. No appreciable differences in the 
apoptotic fraction were observed among the cell lines. 
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Figure 3.5 Cell cycle analysis reveals accelerated cell cycling of Hyal1-
overexpressing cells. Transfectant cell lines were fixed, permeabilized, propidium iodide 
stained and analyzed by flow cytometry. Respective mean percentages of cells in each 
phase of the cycle are plotted ± SEM for a total of three experiments in asynchronous 
cultures (A). Cells were synchronized in the G2/M phase by nocodazole treatment, then 
released by replacement with standard medium for the indicated times and similarly 
analyzed by flow cytometry. Mean ± SEM of triplicate assays is plotted for each phase of 
the cell cycle at each time point as indicated at the top of each column; * p<0.01. Plots 
compare HAS2 (dark blue triangles), Hyal1 (black squares), and Hyal1/HAS2 (light blue 
circles) cells (B) or HAS3 (red triangles), Hyal1 (black squares), and Hyal1/HAS3 
(orange circles) cells (C). 
 
134 
To investigate cell cycle alterations more carefully, we performed a time course 
analysis of cell cycle re-entry following synchronization of the cells with the mitotic 
arrest agent, nocodazole. Comparison of Hyal1 transfectants to GFP controls (Fig 3.5B, 
3.5C) showed a significantly shorter time in G0/G1 resting phase, ≈6-7 hours versus 12-
14 hours, with consequent accelerated advance to S-phase. HAS2 (Fig 3.5B) transfectants 
did not exhibit significantly different characteristics. It was evident that the Hyal1/HAS2 
coexpressing cells failed to synchronize completely so the effect of coexpression on 
specific phases of the cell cycle may be masked. HAS3 transfectants (Fig 3.5C) advanced 
to S-phase more slowly than controls, ≈16-18 hours. Hyal1/HAS3 cotransfectants, though 
entering S-phase at a similar rate to controls, exhibited an S-phase peak of comparable 
magnitude to the Hyal1 cells. Thus, excess HA production has the potential to extend 
time in the resting phase, while Hyal1 expression appears to reduce this time and 
accelerate overall cell cycling. 
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3.4.5 Cell Adhesion and Migration to Collagen are Impaired by HAS Expression 
but Migration is Increased Synergistically with Hyal1 and HAS Coexpression 
Finally, we examined cell adhesion and motility in response to the extracellular 
matrix protein collagen IV, a normal component of the prostate basement membrane. To 
assay adhesion, tumor cell suspensions were applied to collagen-coated microwell plates 
(Fig 3.6A). HAS2 and HAS3 overexpressing cells, which bear abundant pericellular HA 
relative to untransfected, Hyal1 transfected, or Hyal1/HAS cotransfected cells, were 
≈50% less adherent to this substrate. In similar assays, the HAS transfectants were up to 
80% less adherent on fibronectin or laminin coated plates (not shown). Reduced adhesion 
is one likely explanation for the slower growth rate of these cells in vitro, but is not 
necessarily coupled to intrinsic cell motility. To test this, we assayed migration of the 
cells in a modified Boyden chamber (Fig 3.6B). Migration of the HAS transfectants was 
modestly but significantly reduced relative to the GFP controls. Strikingly, although 
Hyal1 individual and Hyal1/HAS cotransfected cells adhered comparably to GFP control 
transfectants, cell migration of Hyal1 transfectants was significantly increased, and 
further enhanced by Hyal1/HAS coexpression. Results of the cell migration assay directly 
reflected the pattern of metastatic potential exhibited. Collectively, results of our 
characterizations in vivo and in vitro, summarized in Table 1, implicate Hyal1 expression 
in enhanced tumor cell intrinsic motility, as well as proliferation, and demonstrate that 
the combined production of HA with the Hyal1 processing enzyme maximizes this 
potential. 
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Figure 3.6 Cell adhesion and migration to collagen are impaired by HAS expression 
but migration is increased synergistically with Hyal1 and HAS coexpression. (A) 
Cell adhesion to type IV collagen (5 μg/ml) was quantified in a precoated 96-well plate, 
to which calcein-labeled tumor cell suspensions were added. Non-adherent cells were 
removed by gentle washing after a 2 h incubation at 37˚C. Remaining adherent cells were 
lysed and fluorescence of each well was normalized to a standard curve for each cell line. 
Results plotted are the mean ± SEM of quadruplicate wells from a total of three 
experiments; * p<0.01. (B) Cell migration was assayed in a modified Boyden chamber. 
Stably transfected 22Rv1 cells as indicated were trypsin released and resuspended in 
serum free RPMI. The lower wells of the chamber contained type IV collagen (10 μg/ml) 
in serum free RPMI. Cells (20,000/well) were placed in quadruplicate wells of the upper 
chamber, separated from the lower wells by a polycarbonate membrane with 8μM pore 
size. After 20 h incubation at 37˚C, membranes were fixed and stained. Migrated cells 
were counted in five random fields per well at 150x magnification. Average number of 
cells per field is plotted ± SEM for each cell line; * p<0.01, **p<0.05. 
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Table 3.1 Summary of transfectant prostate tumor cell characteristics. 
 
 GFP Hyal1 HAS2 Hy1/H2 HAS3 Hy1/H3 
Tumorigenesis 1 1.00 0.43* 6.24* 0.80* 2.03* 
Metastasis 1 2.67* 1.32 6.00* 1.55 4.33* 
Blood vessel density 1 1.11 1.84* 0.81 1.41 1.07 
Apoptosis No significant differences, <5% total cells 
Proliferation 1 1.62* 0.10* 1.14 0.54* 1.00 
Cell cycle 
    Asynchronous (S-phase) 
    Time to S-phase re-entry 
 
 
12-14h 
 
+12% 
6-8 h 
 
 
12 h 
 
 
NA 
 
 
16-18h 
 
+7% 
14-16 h 
Adhesion 1 0.99 0.49* 0.85 0.51* 1.15 
Migration 1 1.95* 0.78* 5.00* 0.60* 2.57* 
 
* p<0.05 relative to GFP control 
NA: not fully arrested 
 
 
 
138 
3.5 DISCUSSION 
Unfavorable prognosis for invasive prostate cancer is strongly correlated with the 
combined presence of HA and Hyal1 in human resected prostate tumor tissue. 
Independently, overexpression of either Hyal1 or HAS has been previously implicated in 
promotion of subcutaneous tumorigenesis in mice16,24-26. However, the respective 
importance of HA synthesis and processing enzymes in prostatic tumor growth kinetics 
and metastatic potential has not been evaluated. In this study, we found that HAS 
expression modestly suppressed prostate tumor cell growth at the orthotopic site, while 
the combined production of HA with excess Hyal1 processing activity served to 
accelerate primary tumor growth kinetics (Table 1). The expression of Hyal1 alone was 
sufficient to initiate spontaneous lymph node metastasis while having no effect on 
primary tumor size, but the simultaneous overproduction of HA further accelerated tumor 
cell dissemination. We demonstrated these differential effects were independent of tumor 
angiogenesis. Rather, they were attributable to altered cell cycle progression in the 
presence of Hyal1 alone, and to increased motility stimulated by Hyal1 but significantly 
enhanced by coexpression of HAS with Hyal1. This is the first study to dissect the 
respective roles of the HA synthesis and processing enzymes in an orthotopic prostate 
cancer progression model and to correlate with underlying cellular mechanisms. 
Tumor cell responses to HA synthesis have been reported by a number of groups. 
Several studies have found HAS overexpression promotes tumorigenesis24 or anchorage 
independent growth27, while others found metastatic frequency increased without 
impacting tumorigenesis28,29. Interestingly, many studies have also shown that large HA 
quantities of high molecular mass (i.e.; >100 kDa) are antiproliferative and 
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antiangiogenic30,31, capable of suppressing growth of both tumor cells16,32 and vascular 
endothelial cells31. These responses are dependent upon both size and concentration of 
HA. In fact, dose dependence of HA production was shown by selection of tumor cells 
for different levels of HAS1 overexpression, which promoted subcutaneous 
tumorigenesis at low levels while suppressing it at high levels33. However, it is clear that 
the turnover of HA is critical for the observed phenotypic outcome of excess HA 
synthesis. HAS was tumorigenic in gliomas only if cells expressed hyaluronidase32. In 
breast cancer cell lines, expression of HAS2 and the hyaluronidase isozyme Hyal2 were 
associated with invasive phenotype34. In our previous work, antisense HAS suppression 
inhibited subcutaneous growth of tumor cells that could be restored by HA 
supplementation19. In addition, concurrent overexpression of Hyal1 and HAS2 increased 
tumor size several fold relative to either Hyal1 or HAS alone16. Collectively, these results 
are consistent with our observations in the work presented here. Importantly, we 
demonstrate that the excess production of HA is growth suppressive to the cells 
synthesizing it, whereas the simultaneous elevation of turnover by Hyal1 provides a 
growth promoting signal. 
HA turnover by Hyal1 may provide an oligomeric HA signal in the extracellular 
space35 that would compete with polymers for receptor binding at the cell surface. 
Alternatively or in addition, Hyal1 may function in concert with Hyal2 to enhance tumor 
cell reuptake of HA polymers36, with the majority of degradation taking place 
intracellularly. We have quantified expression of other hyaluronidase isozymes, including 
Hyal2, and found that although Hyal2 and Hyal3 messages are present, they do not show 
differential expression among human prostate tumor cell lines and their expression did 
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not change with any of our gene manipulations (Simpson, MA, unpublished), nor are 
there any reports of their clinical involvement in prostate cancer. Presumably, these 
enzymes are participating to an equal extent in the phenomena we have examined here. 
Altered receptor engagement subsequent to cellular stimulation by HA polymers 
versus HA oligosaccharides influences signaling pathways for cellular transformation and 
apoptosis (reviewed in5). For example, targeted disruption of the HAS2 gene in mice 
supports the implication of HA as an essential signal for epithelial to mesenchymal 
transition that precedes cardiac septal formation37. This function of HA as a 
transformation signal has been demonstrated in cancer progression as well, in which case 
neoplastic transformations may be promoted by HA-mediated activation of receptor 
tyrosine kinases such as ErbB238-40. Constitutive engagement of HA receptors by small 
amounts of newly synthesized HA polymers was shown to stimulate cell cycling through 
assembly of protein complexes including PI3-kinase, cdc37, and the cytoskeletal adaptor 
ezrin40,41. In addition, HA responses are context dependent with respect to two-
dimensional versus three-dimensional culture conditions4. Anchorage independent 
growth of prostate tumor cells requires HA polymer ligation of cell surface receptors to 
stabilize cytoskeletal architecture by intracellular association with ankyrin, ezrin, 
cytoskeletal proteins and other adaptors41,42. These interactions have been successfully 
disrupted and shown to induce tumor apoptosis in vitro and in vivo by administration of 
HA oligosaccharides41,43. 
A component of HA signaling in transformation may be its influence on cell cycle 
progression through physical processes. Pericellular HA matrices enlarge during mitotic 
cell rounding and this cell-associated HA deposition facilitates de-adhesion during the 
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G2/M phase of the cell cycle44. Intracellular HA was detectable and appeared to interact 
with the mitotic spindle throughout cell division. The authors postulated that its extrusion 
to the cytoplasm could be needed to exert steric or osmotic effects on trafficking of 
intracellular components. Using metastatic Dunning rat prostate tumor cells, Koike et al45 
observed that HA production may be induced in tumor cells by increasing mechanical 
stress as the tumor enlarges, contributing to survival and anchorage independent 
spheroidal growth of the tumor cells. We previously found that exogenously added 
Streptomyces hyaluronidase could relieve the growth inhibition imposed by 
overproduction of HA14. Consistent with our observations in the current study, Hyal1 
isolated from plasma was previously shown to promote cell cycling, evidenced by 
increased cells in the DNA synthesis (S) phase with reduced numbers in the resting 
(G0/G1) phase46; also, G2/M arrest is the outcome of Hyal1 knockdown26. We have 
further shown here that overproduction of HA (but not exogenous HA addition) lengthens 
the duration of G0/G1 and delays S-phase entry. Collectively, these results are consistent 
with a model in which HA is required both within the tumor cell to physically facilitate 
accelerated progression through mitosis, and at the pericellular surface to permit cell 
morphology changes essential to division. In this model, excess HA unbalanced by the 
turnover activity of Hyal1 would inhibit processes such as chromosomal condensation 
and/or DNA synthesis, possibly by steric or electrostatic interference, thus slowing entry 
into G0/G1. The presence of Hyal1 may relieve HA inhibition through enhanced 
clearance if sufficiently expressed to balance synthesis. 
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An additional explanation for altered tumorigenesis and metastasis in conditions 
of HA dysregulation is that HA antagonizes cell adhesion and motility. Excess HA 
accumulation at the cell surface impairs integrin-mediated adhesion, so migration is also 
affected, since cells must adhere and de-adhere to orchestrate nonrandom movements. In 
part because of its anti-adhesive function but also as a result of receptor engagement, HA 
has a prominent role in promoting cell migration. Pericardial explants from HA deficient 
mice, which did not undergo endothelial cell migration needed for cardiac 
morphogenesis, were shown to have restored motility in the presence of exogenous HA 
or dominant negative ras37. Thus, HA can serve as a ras-dependent signal for cell 
migration. A similar role for HA in genitourinary development was shown by monitoring 
prostate ductal branching in embryonic explants47. In renal proximal tubular epithelial 
cells, HA directly stimulates migration through MAP kinase activation48 and also 
suppresses the anti-migratory TGFβ1 signal normally produced by the cells49. 
Pericellular HA synthesis in response to prostate fibroblast conditioned media has been 
observed to correlate with increased migration of prostate tumor cells50, where HA was 
most densely deposited at the trailing edge of the polarized motile cells, consistent with 
its potential role in de-adhesion. However, the overexpression of HAS isozymes has also 
been shown to reduce motility51, as we have seen in the current report. In neither of these 
prior cases was hyaluronidase activity investigated, however, so it is probable that HA 
turnover differed among the cells tested, and that such differences contribute to the net 
effect of HA production on cell motility. This notion is supported by our findings of 
dramatically increased motility in the Hyal1/HAS transfectants: cells continually 
synthesize the anti-adhesive surface HA, but since they rapidly turn it over, streaming 
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and reattachment during movement are not hindered. 
In summary, our finding that cell adhesion and motility are respectively restored 
and enhanced by concurrent elevation of HA synthesis and HA turnover enzymes 
supports the implication of HA in suppressed adhesion, growth and migration of tumor 
cells. Thus, the observation of HA accumulation within tumor tissue is not necessarily an 
intrinsic negative prognostic factor and its presence alone is not carcinogenic. In 
particular, we have consistently found that effects of HA on growth and motility are 
dependent on cells synthesizing the HA, and cannot be recapitulated with exogenous 
addition of HA to cultures or assays. Rather, the subsequent or concurrent infusion of 
hyaluronidase, regardless of cellular origin, leads to accelerated tumor growth and 
metastatic spread that is potentiated in the presence of excess HA production. We 
propose that more rapid cell cycling and proliferation underlie Hyal1-mediated 
metastasis, while Hyal1/HAS cotransfectants are metastatic due to enhanced motility, 
independently of any potential effects on tumor angiogenesis. Motility is not increased as 
a result of altered extracellular matrix adhesion, but may result from differential use of 
adhesion receptors. Since exogenous, extracellular hyaluronidase in vitro and in 
subcutaneous tumors also acts on tumor-borne HA, the results collectively imply that 
prostate tumor epithelial and stromal cells must both be targeted in therapeutic strategies 
involving inhibition of HA production or turnover. 
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CHAPTER 4 
 
DIFFERENTIAL ERK ACTIVATION AND REGULATION OF CELL CYCLE CHECK 
POINT PROTEINS BY ALTERED HA METABOLISM 
153 
4.1 ABSTRACT 
HA plays a crucial role in prostate tumorigenesis and metastasis. We have shown 
previously that maximum tumorigenic and metastatic potential of HA is obtained by 
concurrent expression of hyaluronan synthase (HAS) and hyaluronidase (Hyal1). These 
effects were chiefly due to enhanced cell proliferation, adhesion and motility in the co-
expressing cells. In contrast the cells expressing HAS alone, showed growth suppression 
in vitro and in vivo and reduced motility. Detail characterization of cell cycle progression 
in these cells revealed that expression of Hyal1 alone caused accelerated entry into cell 
cycle, whereas HAS alone caused diminished entry. In the present study we establish that 
the altered cell cycle kinetics in these cells is predominantly mediated by the reduced 
expression of the cyclin dependent kinase inhibitor (CKIs) p21cip (p21) in Hyal1 
expressing cells, whereas the HAS expressing cells showed increased expression of both 
CKIs p21cip (p21) and p27kip (p27), in both asynchronous and synchronized cultures. We 
also demonstrate that the growth factor induced ERK activation was significantly reduced 
in Hyal1 expressing cells compared to HAS3 and control (GFP) transfectants. These 
studies institute a mechanistic correlation between the tumorigenesis effects observed 
earlier, as a consequence of altered HA metabolism. 
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4.2 INTRODUCTION 
Hyaluronan (HA) is a high molecular weight glycosaminoglycan polymer of 
alternating glucuronic acid and N-acetylglucosamine that functions in normal and 
pathological tissue to influence cell motility and proliferation1. In radical prostatectomy 
specimens from prostate cancer patients, concurrent positive staining for HA and its 
degradative/turnover enzyme, the hyaluronidase Hyal1, predicts poor prognosis and 
patient outcome2. In animal models, it has independently been shown that HA 
overproduction by HA synthase enzymes3, and elevated hyaluronidase activity conferred 
by Hyal1 overexpression4, will each promote tumor growth dose dependently, but will 
also suppress tumor growth at levels beyond a threshold value. Thus, it is important to 
characterize the respective roles of the HA synthases and hyaluronidases in component 
processes of tumor progression such as motility and proliferation. 
Previous work in our laboratory has shown that overexpression of HAS2 and 
HAS3 in non-metastatic prostate tumor cells accelerates growth and lymph node 
metastasis of orthotopic tumors in mice, but only in the presence of Hyal1, which can 
also accelerate metastasis independently5. When we characterized these stably transfected 
cell lines in vitro, we observed that overexpression of HAS2 or HAS3 reduced growth in 
culture, whereas Hyal1 transfectants grew faster than the stable control cells. Addition of 
exogenous hyaluronidase to HA over-producing cell lines also relieved growth inhibition 
by HA polymer production. Similarly, motility was enhanced by expression of Hyal1, 
either alone or in conjunction with HAS. Analysis of cell cycle distribution in 
asynchronous cultures showed specifically an increase in number of Hyal1 transfectants 
in S-phase with concurrent reduction in G0/G1 phase cells. Using nocodazole 
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synchronized transfectants, the increased number of S-phase cells was explained by 
accelerated re-entry of Hyal1 transfectants to S-phase upon release from arrest. In 
contrast, HAS3 transfectants reached and completed S-phase significantly more slowly 
than control cells. These studies have determined that the predominant mechanism of 
growth control in the Hyal1 and HAS+Hyal1 transfectants is through alterations in DNA 
synthesis and cell cycle progression kinetics, prompting us to investigate the molecular 
signals linking Hyal1 hyaluronidase and modulation of cell cycle regulatory proteins. 
Progression through the cell cycle is dependent on external signals in the 
microenvironment until a point in the cell cycle known as the restriction point6, beyond 
which the cell is committed to proceed through the cycle irrespective of external cues. 
Growth factors or mitogens, integrins and extracellular matrix (ECM) proteins are among 
the signals crucial for tight regulation of cell cycle progression through specific 
cascades7. The Ras/extracellular-signal-regulated kinase (ERK) mitogen activated protein 
(MAP) kinase pathway is critical for transmission of extracellular signals to the 
nucleus8,9. Nuclear ERK phosphorylates transcription factors that activate an array of 
immediate early genes, such as cyclin D1, which are responsible for cell cycle control10. 
In response to growth factors or ECM adhesion, passage through the restriction point is 
determined by induction of cyclin D1, followed by its binding to the cyclin dependent 
kinases CDK4/6, which in turn are activated to phosphorylate the protein Rb. 
Hyperphosphorylation of Rb results in the release of E2F transcription factors, inducing 
cyclin E and cyclin A during G1/S-phase transition and peak S-phase. To counteract the 
effect of the CDK, a group of proteins known as cyclin dependent kinase inhibitors (CKI) 
bind to and inactivate the CDKs, thereby stalling progression through the cell cycle. Two 
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CKIs, p21Cip and p27Kip bind to CDK4/6 during G1 phase and to CDK2 during S-phase, 
inhibiting progression through these phases11-14. 
In this study we have investigated the effect of cell cycle arrest and release on 
ERK phosphorylation in prostate tumor cells expressing HAS and Hyal1 genes and the 
subsequent status of various cell cycle regulatory proteins. We show that there is no 
compromised transient or sustained ERK activation in response to growth factors such as 
EGF and bFGF in cell expressing HAS enzymes despite the reduced growth and cell 
cycle entry in these cells. Interestingly we observed significant downregulation of p21 in 
Hyal1 and Hyal1+HAS3 expressing cells, in contrast to the HAS expressing cells, in 
which levels of both p21 and p27 were increased. Thus, regulation of CKI is one 
potential mechanistic explanation for the differential effects of HA metabolism on cell 
cycle progression and tumor growth. 
 
4.3 MATERIALS AND METHODS 
 
4.3.1 Cell Culture, Materials, and Reagents 
22Rv1 human prostate adenocarcinoma cells15 were purchased from ATCC and 
maintained in RPMI 1640 medium containing 10% fetal bovine serum. Selection, 
characterization, and maintenance of 22Rv1 stable transfectants in standard medium 
containing 1.5 mg/ml G418 was carried out as described previously15. The pIRES2-EGFP 
vector and plasmids pTet-On and pTRE-Tight that comprise the tetracycline-inducible 
mammalian expression system were obtained from Clontech (Palo Alto, CA). 
Doxycycline and Tet System-approved fetal bovine serum were also from Clontech. 
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Antibodies against ERK1/2, phosphorylated ERK1/2, Cyclin A, Cyclin D1, p21 and p27 
were from Cell Signaling Technologies (Beverly, MA). The anti-tubulin antibody and 
nocodazole were purchased from Sigma. EGF and bFGF were obtained from R&D 
Systems (Minneapolis, MN). 
 
4.3.2 Growth Factor Stimulation of Prostate Tumor Cell Lines 
For transient activation of ERK1/2, stable transfectants were seeded at 4x105 cells 
per well of a 6-well plate in serum containing media. Subconfluent cells were serum 
starved for 24 hours, then treated with a cocktail of EGF (20 ng/ml) and bFGF(10 ng/ml). 
After 20 mins, cells were washed twice in 1x PBS and harvested in 
Radioimmunoprecipitation assay buffer (RIPA: 50mM Tris-HCl, pH 7.5, with 150mM 
NaCl, 1% NP-40, and 0.25% sodium deoxycholate) lysis buffer containing 2mM PMSF, 
2mM sodium orthovanadate, 2mM sodium fluoride, 1x phosphatase inhibitor cocktail 
(Pierce), and protease inhibitor cocktail (Sigma). The harvested cells were quickly 
snap/flash frozen under liquid nitrogen and stored at -800C until further use. For long 
term evaluation of ERK1/2 activation, 24 hour serum starved cells were treated with 
growth factor cocktail (20ng/ml EGF+10ng/ml bFGF) and cell were harvested at 0hrs, 
3hrs, 6hrs, 12hrs and 24 hrs using the RIPA lysis buffer described above. 
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4.3.3 Cell Synchronization 
Cells were synchronized at G2/M phase using the mitotic inhibitor nocodazole 0.2 
μM for 24hrs and washed three times with serum free media. The cells were then 
released with serum free media containing the growth factor cocktail described above and 
harvested by lysis in RIPA buffer at 0 hr, 3hr, 6hr, 12hr and 24 hrs after release. 
Asynchronous cells were harvested from 6-well plates which were seeded in serum 
containing media. 
 
4.3.4 Kinase Inhibitor Treatment 
Subconfluent cultures of stable transfectants were treated with 10µM of U0126 
(MEK inhibitor) or 100nM of Wortmannin (PI3K inhibitor) for two hours. The cells were 
washed with 1x PBS and harvested in RIPA lysis buffer with protease and phosphatase 
inhibitors. Equivalent amounts of protein (10 µg) were separated by SDS-PAGE and 
probed using anti-phospho-ERK, total ERK and tubulin antibodies. 
 
4.3.5 Western Analysis 
Protein content was adjusted to equivalent levels in all cell lysates following 
quantification by Bradford assay. Ten µg of total protein were separated by SDS-PAGE 
and transferred to PVDF membrane. Blocked membranes were probed for ERK1/2 
(1:1000), phosphorylated ERK (1:1000), cyclin A (1:2000), cyclin D1 (1:2000), p21 
(1:2000, or p27 (1:1000), then stripped and reprobed for the tubulin loading control 
(1:500,000). The blots were developed using ECL system (Amersham/GE Healthcare, 
UK). 
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4.3.6 Densitometry Analysis of Western Images 
The bands obtained from immunoblots were quantified using the Totallab TL100 
V2006b software at the Proteomics Core facility of UNL. Individual protein bands were 
normalized to tubulin control. The data are representative of two or three independent 
experiments showing similar trends. 
 
4.3.7 Characterization of Tet-inducible 22Rv1 Cells 
A 22Rv1 stable line expressing the tetracycline transactivator (as described 
previously16) was transfected with pTRE-Tight derived plasmids expressing the GFP 
(control), Hyal1, and HAS3 coding sequences under the control of a tetracycline 
responsive promoter. The transfectants were induced by applying 2μg/ml of doxycycline 
and soluble extracts were prepared for western analysis at 48hrs post induction. The 
supernatants were harvested and processed as described15,16 for quantification of HA in 
the HAS3 expressing cells. 
To determine the proliferation rate of the cells transiently transfected with GFP, 
Hyal1 and HAS3, triplicate wells for each cell line were seeded in 24 well culture dishes 
24 hours after transfection. The cells were induced with 2μg/ml of doxycycline 24 hours 
after plating and the growth was monitored daily for a period of five days by manual 
counting. Total number of cells per well were plotted for each day in culture. The plot 
shown is representative of four independent experiments. 
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4.4 RESULTS 
 
4.4.1 EGF and bFGF Activate ERK Comparably in Prostate Tumor Cell 
Transfectants 
Our previous studies have demonstrated that HA levels directly correlate with the 
suppression of intrinsic growth rate in culture. Expression of Hyal1 enhanced intrinsic 
proliferation in culture. To determine the molecular mechanism for these altered growth 
kinetics, we decided to evaluate the growth factor signaling pathway in these cells. The 
ERK pathway regulates cellular proliferation, differentiation, migration and invasion in 
tumor cells. The ERK cascade is a central element in the transmission of signals from the 
cell surface to the nucleus. With the idea that ERK is a common downstream effector and 
that multiple pathways converge on ERK, we evaluated the effect of growth factors on 
ERK activation in cells overexpressing Hyal1 and HAS3. These cell lines were chosen 
initially since we saw significant difference in cell cycle progression kinetics between 
Hyal1 and HAS3 stable transfectants. GFP control, Hyal1 and HAS3 transfectants were 
serum starved for 24 hours, then treated with EGF and bFGF for 20 mins and analyzed by 
western blot for levels of transiently activated phospho-ERK relative to total ERK. As 
shown in Fig 4.1, the phospho-ERK level was negligible in untreated cells, but increased 
dramatically in all three lines upon growth factor addition. The level of phospho-ERK 
was consistent among the three transfectants. 
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Figure 4.1 EGF and bFGF activate ERK comparably in prostate tumor cell 
transfectants. Transient activation of ERK in stable cell lines expressing GFP (control), 
Hyal1(Hy1) and Has3(H3) in response to growth factors. We treated 24 hours serum 
starved cells with growth factor cocktail (GF) composed of 20ng/ml of EGF and 10ng/ml 
of bFGF for 20 mins. Untreated cells (-) and treated cells (+) in each case were harvested 
and lysed in RIPA buffer with protease and phosphatase inhibitors. The cell lysates were 
collected and ERK1/2 phosphorylation was assessed by western blot analysis. The blot is 
representative of three independent experiments. 
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4.4.2 Hyal1 Overexpression Reduces Sustained ERK Activation without Altering 
Cyclin D1 
The MAPK-ERK pathway is known to elicit different biological outcomes 
depending on the duration, magnitude and temporal activation of ERK9,10. Sustained 
ERK activation is critical for inducing immediate early genes during the G1 phase. One 
of these, cyclin D1, is needed for cell cycle re-entry and progression into S-phase, and is 
not induced by transient activation of ERK17-20. We evaluated the effect of growth factors 
on sustained ERK activation and cyclin D1 expression in the Hyal1 and HAS 
transfectants (Fig 4.2). Serum starved cells were treated with EGF and bFGF for 3h and 
12h, which correspond to mid G1 and late G1, respectively. Serum starvation (SSM) did 
not decrease phospho-ERK levels relative to cells in serum containing media (AS). 
Growth factor treatment of serum starved cells resulted in significant increase in 
phospho-ERK levels, in all three cell lines at 3h after stimulation (GF+3h). Total ERK 
levels were uniform in all conditions tested. This increase in phospho-ERK was sustained 
up to 12h (GF+12h) in control and HAS3 cells. However, in Hyal1 expressing cells, 
phospho-ERK was already significantly reduced at 3h after growth factor stimulation and 
remained low at 12h. Levels of cyclin D1 were not altered by serum starvation or growth 
factor stimulation in any of the cell lines (Fig 4.2). However, as previously reported by 
others21, cyclin D1 levels were reduced in serum starved normal fibroblasts and epithelial 
cells and were elevated by growth factor induced ERK activation22,23. This is consistent 
with our prior evaluation of these cells, in which we were unable to synchronize cultures 
by serum starvation. Cyclin D1 overexpression may account for failure of these cells to 
synchronize in G0/G1 phase. 
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Figure 4.2 Hyal1 overexpression reduces sustained ERK activation without altering 
cyclin D1. Cell populations in serum containing (AS) or serum deficient (SSM) media 
were treated with growth factor cocktail (GF) composed of 20ng/ml EGF and 10ng/ml 
bFGF for 3h (GF+3h), and 12h (GF+12h). Cells were harvested and lysed in RIPA buffer 
with protease and phosphatase inhibitors and analyzed by western blot probed with the 
indicated antibodies (left). Densitometric quantification of p-ERK2 to t-ERK2 ratio and 
cyclin D1 to tubulin ratio is shown at right. Data are from one blot representative of three 
independent experiments. 
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4.4.3 Hyal1 Overexpression Reduces Growth Factor Mediated ERK Activation in 
Synchronized Cells 
We have shown previously that treatment with nocodazole, a microtubule 
inhibitor arrested 80-85 % of the 22Rv1 transfectant populations in G2/M phase and on 
release with serum, they progressed through the cell cycle. Therefore, we tested whether 
there were differences in ERK activation when cells were arrested with nocodazole and 
released from arrest by addition of growth factors. Examination of phospho-ERK levels 
in arrested cells revealed a significant increase in all three cell lines (Fig 4.3). This is 
consistent with findings in several studies that show microtubule destabilizing agents 
activate kinases such as p38, ERK and JNK.24-26. 
When cells were released from arrest by growth factor addition, ERK activation 
was sustained, as observed in response to growth factor treatment of serum starved cells 
(Fig 4.2). Hyal1 expressing cells again showed reduced levels of phospho-ERK at 12h 
after growth factor stimulation. Thus, although there was no significant difference in 
transient activation of ERK in cells expressing Hyal1 and HAS3 sustained ERK 
activation by growth factors is significantly diminished in Hyal1 cells. 
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Figure 4.3 Hyal1 overexpression reduces growth factor mediated ERK activation in 
synchronized cells. GFP (control), Hyal1(Hy1) and Has3(H3) expressing cells were 
synchronized with 0.2µM nocodazole in serum free media for 24hours. Cells were 
released with GF cocktail as described in the Fig 2 legend, and harvested at 3h and 12h 
post release. The total protein was assessed for ERK phosphorylation by western blot 
(above) and quantified by densitometry (below). The data shown are representative of 
three independent experiments. 
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4.4.4 Basal ERK Activation in Prostate Tumor Cells is Inhibited by the MEK 
Inhibitor U0126 
The 22Rv1 prostate tumor cells showed increased basal phospho-ERK levels 
which were not modulated by serum starvation. To investigate the upstream pathway that 
is responsible for ERK activation we treated the cells with U0126 a specific inhibitor for 
both MEK1 and 2 and Wortmannin, which targets the PI3K pathway (Fig 4.4). We 
observed complete depletion of phospho-ERK levels in cell treated with U0126 in control 
(GFP), Hyal1, HAS3, and Hyal1+HAS3 transfectants. PI3K inhibitor wortmannin failed 
to elicit any inhibition in these cells. This suggests that the constitutive ERK activation in 
these prostate tumor cells is due to the activation of the Ras/Raf/MEK pathway and not 
due the PI3K pathway. The uniform inhibition of phospho-ERK levels in all the 
transfectants suggest that there is no difference in ERK activation pathway due to 
constitutive expression of HA metabolic enzymes. 
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Figure 4.4 Basal ERK activation in prostate tumor cells is inhibited by the MEK 
inhibitor U0126. Subconfluent cultures of 22Rv1 stable transfectants were treated with 
vehicle (DMSO), 10µM UO126 (MEK inhibitor) and 100nM Wortmannin (PI3K 
inhibitor) for 2 hours. The cells were harvested and equivalent protein was assessed by 
western blot for p-ERK, t-ERK and Tubulin. 
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4.4.5 Expression of Cyclin Dependent Kinase Inhibitors in Hyal1 and HAS3 
Transfectants Inversely Reflects their Growth Kinetics 
Since we did not observe regulation of cyclin D1 protein levels by growth factors, 
we examined additional cell cycle regulatory components that could underlie the altered 
growth of these cells. Cell cycle kinase inhibitors p21cip (p21) and p27kip (p27) also 
regulate cell cycle progression. We analyzed p21 and p27 in asynchronous cultures of 
transfectants expressing Hyal1, either HAS2 or HAS3, and Hyal1+HAS3 cotransfectants 
(Fig 4.5A). p21 protein levels were significantly lower in Hyal1 and Hyal1+HAS3 cells 
compared to control GFP. In contrast and consistent with their slower proliferation, 
HAS2 and HAS3 transfectants had 2.3 fold higher p21 expression than controls. 
Similarly, p27 protein was modestly higher in HAS2 and HAS3 expressing cells (2 fold), 
relative to controls. In Hyal1 and Hyal1+HAS3 expressing cells, there was no significant 
change in p27. 
To determine if p21 and p27 protein levels are modulated during cell cycle 
progression, we synchronized cells with nocodazole (Noc Arr) and probed for p21 (Fig 
4.5B) or p27 (Fig 4.5C) at 12h after release with growth factor addition (Rel+GF+12h). 
Nocodazole arrest reduced p21 and p27 slightly in all three cell lines. However, 
expression of both proteins remained lower in Hyal1 transfectants relative to control or 
HAS3 cells. The expression of p21 was elevated in both Hyal1 and HAS3 lines at 12h 
after release from arrest by mitogen addition, with HAS3 cells exhibiting the greatest 
increase. 
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Figure 4.5 Expression of cyclin dependent kinase inhibitors in Hyal1 and HAS3 
transfectants inversely reflects their growth kinetics. (A) Equal amounts of protein 
from serum replete asynchronous cultures of 22Rv1 stable transfectants expressing GFP 
(control), Hyal1 (Hy1), HAS2 (H2), HAS3 (H3) and Hy1+HAS3 (Hy1H3) were analyzed 
by western blot for p21, p27, and tubulin control. The right panel is a densitometric 
representation of the immunoblots. Nocodazole synchronized (Noc Arr) cells were 
released with GF cocktail as described above. The cells were harvested at 3h and 12h 
post release and assessed for p21 (B) and p27 (C) in comparison to asynchronous (AS) 
and synchronized (Noc Arr) cells. 
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Overall, the level of both p21 and p27 was decreased in Hyal1 clones and the 
level of both p21 and p27 was increased in HAS3 clones. Expression of p21 in control 
cells did not change in response to mitogen, whereas both Hyal1 and HAS3 showed an 
increase. This result suggests that the predominant effect on cell proliferation and cell 
cycle progression in cells expressing Hyal1 and HAS is through altered protein levels of 
the CKIs. 
 
4.4.6 Inducible Expression of Hyal does not Enhance Cell Proliferation and 
Downregulate p21 
To supplement the results obtained for p21 expression with constitutive 
expression of Hyal1 and HAS, we evaluated expression of p21 in Tet-22Rv1 cells 
transiently induced for expression of Hyal1 and HAS3. Tet-22Rv1 cells were transfected 
with GFP (control), Hyal1 and HAS3 plasmids with the tet-responsive promoter using 
equivalent DNA concentration for each plasmid. Cells were analyzed 48 hrs post 
induction with doxycycline (Dox) (Fig 4.6A). The p21 protein levels increased upon 
induction with doxycycline for all three transfectants. The level of p21 was lowest for the 
control GFP in the absence of Dox, and highest in Hyal1 and HAS3 induced cells. This 
observation was in contrast to our previous observation with the constitutive clones, 
where Hyal1 overexpression showed reduced p21 protein levels in both asynchronous 
and synchronized cultures. 
To investigate underlying causes of this difference, we tested the growth kinetics 
of cells induced for Hyal1 and HAS3 expression (Fig 4.6B). The Tet-22Rv1 cells were 
transfected and grown in the absence (-D) or presence (+D) of doxycycline for five days. 
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Reduction of growth upon induction of GFP became significant, but not until day five 
(p<0.05). Surprisingly, induction of Hyal1 also showed significant impact on growth at 
days four and five, which was markedly reduced relative to both induced and uninduced 
GFP controls. In the case of HAS3 transfectants, induction significantly reduced growth 
at day one, which remained depressed on subsequent days. Activity of the induced 
transgenes in each of the above lines was confirmed by western blot for expression of 
Hyal1, and by HA content of the conditioned media for HAS3 (Fig 4.6C). Like GFP 
controls, Hyal1 transfectants lacked Flag epitope signal in the absence of Dox (-), but 
upon induction (+) showed robust expression. Similarly, we observed negligible HA 
production in GFP control cells, with a moderate elevation in uninduced HAS3 
transfectants that increased ≈30-fold with induction. 
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Figure 4.6 Inducible expression of Hyal does not enhance cell proliferation and 
downregulate p21. 22Rv1 Tet-ON cells were transiently transfected with constructs 
encoding GFP, Hyal1 or HAS3 under the control of a Tet sensitive promoter. (A) 
Expression of p21 was determined in cells uninduced (-) and induced (+) with 1µg/ml of 
doxycyline (Dox). (B) Growth of inducible transfectants was assayed by plating equal 
numbers of 22Rv1 Tet-ON 22Rv1 cells transiently transfected with inducible GFP (G), 
Hyal1 (Hy1) or HAS3 (H3) constructs in the absence (G-D, Hy1-D, H3-D) or presence 
(G+D, Hy1+D, H3+D) of 1 µg/ml doxycycline. (C) Expression of Hyal1 protein in 
transiently induced cultures was verified along with constitutive Hyal1 stable clone using 
anti-flag antibodies. 
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4.5 DISCUSSION 
The goal of the present study was to elucidate the mechanisms of altered cell 
cycle progression in Hyal1 and HAS3 overexpressing cells that differ in their tumorigenic 
and metastatic potential. Our studies have identified a potential mechanism for the effects 
of Hyal1 and HAS3 overexpression on prostate tumor cell proliferation, cell cycle 
progression kinetics and tumorigenesis. The S-phase entry is principally regulated via 
CKIs and not via cyclin D1 in these prostate tumor cells. 
Sustained ERK activation mediates direct phosphorylation and stabilization of 
transcription factors, thereby prolonging their expression and activity as opposed to 
transient activation, in which case transcription factors are unstable and degraded10. 
Although there was no difference in transient ERK activation among Hyal1 and HAS3 
expressing cells, we did observe reduction in sustained ERK activation in Hyal1 
expressing cells. This is consistent with studies in which exogenous high molecular 
weight HA did not compromise mitogen induced ERK activation27. Increased HA 
production by HAS2 overexpression in cancer cell lines has been found to constitutively 
activate multiple cell surface growth factor receptors, including EGFR and ERBB2, in a 
CD44 dependent manner28. Growth factor mediated sustained ERK activation usually 
upregulates cyclin D1. However, we did not observe any significant differences in cyclin 
D1 protein among Hyal1 and HAS3 tumor cell transfectants in any conditions tested, 
despite an increase in sustained ERK activation. The most obvious explanation is that 
tumor cells already overexpress cyclin D1 and are insensitive to further stimulation29. 
Although androgen has been shown to modulate cell cycle progression via cyclin D1 in 
the parent CWR22 cell line30, 22Rv1 cells have largely lost androgen dependence and 
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may be unresponsive to this alternative mode of cyclin D1 regulation. Similarly, 
exogenous HA polymer has been shown to reduce S-Phase entry in quiescent vascular 
smooth muscle cells and fibroblasts primarily by decreasing cyclin D1 protein levels31. In 
our HAS3 overexpressing cells, cyclin D1 is unaffected by mitogen, suggesting 
exogenous and endogenous HA acts by different mechanisms. 
We observed that intrinsic phospho-ERK levels are elevated in 22Rv1 prostate 
tumor cells. ERK is activated primarily by the Ras/Raf/MEK pathway by growth factors 
and integrins, but can also be phosphorylated downstream of PI3-kinase via PKC 
indirectly and via Centaurin-α1 directly32,33. Inhibition of MEK eliminated ERK 
phosphorylation while a PI3-kinase inhibitor had no effect, indicating that the 
predominant pathway for ERK activation in our system was via Ras/Raf/MEK. The 
22Rv1 prostate tumor cells overexpress ERBB2 (HER2) and EGFR receptors34, which 
would be expected to promote hyperactivation of Raf/Ras/MEK. This is a possible 
explanation for the elevated basal level of ERK in 22Rv1 parental and transfected cells. 
Assessment of the two CKIs p21 and p27 in asynchronous and nocodazole 
synchronized cell populations revealed that p21 and p27 protein levels were reduced in 
rapidly proliferating Hyal1 transfectants, while these levels were increased in the slower 
growing HAS3 cells. This finding is consistent with the well established role of p21 and 
p27 as negative regulators of the cell cycle35,36, and stands in contrast to increasing 
evidence suggesting p21 can also act as a positive modulator of cell proliferation and 
tumorigenesis37-41. It is worth bearing in mind that the inhibitory potential of p21 is 
dependent on cellular context, phosphorylation state and protein-protein interaction35. 
The upregulation of p21 protein levels in Hyal1 expressing cells 12h after growth factor 
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stimulation suggests it is involved in promoting G1/S transition in these cells. Small 
amounts of p21 bound to the cyclin/CDK complexes activate the complex for cell cycle 
progression, whereas higher amounts inhibit the complex13. Therefore, the opposite result 
occurs upon induction of p21 in HAS3 transfectants, which already have high levels: that 
is, the increased p21 level inhibits growth. A further explanation for the opposing effects 
of p21 and p27 upregulation on Hyal1 versus HAS3 transfectants is that these proteins 
also bind to proliferating cell nuclear antigen (PCNA), a DNA polymerase δ processivity 
factor, thereby blocking DNA synthesis42. The reduced protein level of p21 in Hyal1 
expressing cells is a plausible mechanism for enhanced DNA synthesis and S-phase 
entry, while the increased p21 observed in HAS3 cells would conversely reduce DNA 
synthesis. Finally, it has also been previously reported that binding of HA polymers to 
CD44 antagonized S-phase entry in smooth muscle cells, and that this occurred through 
stabilization of p27 via inhibition of Skp2, a component of the p27 degradation 
machinery31,43. Our data showing p27 remained elevated in HAS3 up to 12h after 
mitogen stimulation are consistent with this regulatory scheme. 
One of the possible implications of downregulated p21 in asynchronous and 
synchronized Hyal1 transfectants could be reduced DNA damage response. In this study, 
we have shown that the shorter residence time in G2 and G1 phase after nocodazole 
arrest that we observed in Hyal1 transfectants5 is due to decreased p21 levels. Since p21 
is required in DNA damage induced cell-cycle arrest, Hyal1 expressing cells may 
continue to synthesize DNA in the absence of proofreading, thus propagating genomic 
instability. In contrast, the HAS3 expressing cells may evade such damage by slower 
entry into the cell cycle, and are therefore less tumorigenic. We are currently testing the 
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effects of DNA damage agents and pathways therein to test this possibility. 
The magnitude of ERK activation is important not only in cell cycle progression 
but also in cell cycle arrest. The ERK pathway was shown to cause cell cycle arrest in 
primary hepatocytes by increased expression of p2144-48. Consistent with this, our study 
showed increased ERK activation in HAS3 transfectants at 12h after growth factor 
stimulation, a time at which we also observed increases in p21. Moreover, Hyal1 showed 
only moderately increased ERK activation at 12h, and also had only a slight increase in 
p21 levels, probably not sufficient to cause cell cycle arrest. Further studies using specific 
inhibitors that block ERK activation in response to growth factors are warranted to 
determine if it has a direct bearing on the induction of p21 in HAS3 expressing cells. Our 
studies also have not addressed the reason for differences in magnitude of ERK activation 
among the cells expressing Hyal1 and HAS3. The amplitude, duration, and quality of 
signals generated by a given ligand such as growth factors are functions of receptor 
activation states, quantities, and locations that are determined by regulated intracellular 
trafficking10,49. It would be interesting to determine if there are differences in endosomal 
trafficking and growth factor receptor internalization in cells overexpressing Hyal1 or 
HAS3. It may be informative to perform a gene expression profile of cells treated with 
growth factors at the time points where we observe differences in ERK activation, thus 
directly correlating genes upregulated and/or downregulated due to the magnitude of 
ERK activation. 
To support our observations for the effect of Hyal1 and HAS3 constitutive 
overexpression on CKIs p21 and p27, we used our inductible expression system. In these 
experiments, p21 expression was not downregulated by induction of Hyal1 as we 
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observed with the constitutive clones. On the contrary, we observed increased p21 levels 
compared to the GFP controls. However, we also observed an increase in p21 protein 
level on induction of HAS3, which is consistent with results of constitutive HAS3 
expression. Although constitutive expression of Hyal1 significantly increased intrinsic 
growth rate of cells5,15,16 compared to control and HAS3 transfectants, transient induction 
of Hyal1 had the opposite effect. One probably explanation for this effect is that the 
Hyal1 protein level is considerably higher in the induced versus constitutive cell lines. 
Hyal1 expression has previously been shown to have a concentration dependent effect on 
cell proliferation: that is, low Hyal1 promoted growth while high Hyal1 induced 
apoptosis of tumor cells4. Evaluation of apoptosis in our induced cells is underway to 
confirm whether this is occurring. Another complicating factor is that we also observed 
decreased growth of cells induced for GFP expression. This suggests increased 
doxycycline, and/or sudden induction of large-scale protein production, might generally 
reduce growth, partly contributing to the Hyal1 induced decrease in growth we observed. 
Nonetheless, both induced and constitutive HAS3 expression reduced intrinsic cell 
growth16. Here we correlated growth reduction with p21 levels, which are modestly 
elevated by HAS3 expression. We propose the differences in growth and other 
tumorigenic phenotype between the constitutive and inducible systems may also be 
attributable to stable adaptation to long term expression of Hyal1 or HAS3. We are now 
doing experiments to systematically assess the effects of concentration dependence of 
Hyal1 expression on growth by varying the levels of dox/induction (used for induction). 
This will allow us to control the Hyal1 expression and simultaneously monitor its effect 
on growth and p21 protein levels. 
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In summary, we have discovered a plausible signaling mechanism for the altered 
growth and cell cycle kinetics of prostate tumor cells in response to altered HA 
metabolism. We propose that modulation p21 and p27 protein expression could be a 
potential mode of regulation in these prostate tumor cells. 
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CHAPTER 5 
 
SUMMARY AND FUTURE DIRECTIONS 
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5.1 SUMMARY 
Hyaluronan (HA) has been regarded as an important extracellular matrix (ECM) 
involved tumor growth and progression. The studies described in the previous three 
chapters of this thesis have contributed to the understanding of the role of HA in tumor 
development. We understand that HA does not merely play a mechanical and structural 
role facilitating the migration of tumor cells in ECM, but is actively involved in 
regulating cellular processes governing tumor progression such as tumor cell proliferation 
and motility. 
The primary focus of our studies has been to dissect the respective roles of the 
HA metabolic enzymes, hyaluronan synthases and hyaluronidases, in prostate tumor 
progression. To complement correlative studies between HA/Hyal1 and poor patient 
prognosis in prostate cancer, we used gene manipulation techniques to overexpress the 
synthases HAS2 and HAS3 and the hyaluronidase Hyal1 in a non-metastatic prostate 
tumor cell. Using both in vitro and in vivo characterizations, we established that 
concurrent expression of HAS and Hyal1 is necessary for maximum tumorigenesis and 
metastasis. Overproduction of large quantities of HA polymer causes suppression of 
tumor growth and spontaneous lymph node metastasis. This is correlated with poor 
growth of cultured cells in vitro (chapter 2 and 3), and decreased migration in response to 
ECM substrates such as collagen (chapter 3). Interestingly, supplementation of 
exogenous hyaluronidase or coexpression of Hyal1 restored the growth in vitro and also 
enhanced tumor growth and metastasis in vivo. The increase in metastasis correlated well 
with increased adhesion and migration to collagen. Decreased integrin mediated adhesion 
of HAS expressing cells could not only explain the reduced metastatic potential of these 
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cells but could also account for the growth suppressive properties of HA. Adhesion is 
critical for tumor cell motility, but also plays a critical role in regulating apoptosis, cell 
cycle and proliferation. Most importantly, turnover of excessive HA is critical in 
mediating enhanced adhesion and motility. Thus, our studies show that excess HA in 
tumors by increased synthesis is not necessarily a negative indicator of tumor progression 
and presence of HA alone is not tumorigenic. We now understand exogenous HA does 
not promote the same effects on prostate tumor cells as cells actually synthesizing the 
HA. In contrast, both exogenous hyaluronidase and Hyal1 synthesized by the tumor cell 
itself promote cell growth and metastasis only in the presence of excess HA. 
Tumor growth and metastasis were independent of angiogenesis. We believe the 
increased proliferation and metastasis of Hyal1 transfectants was largely dependent on 
accelerated cell cycling and enhanced cell motility. Metastasis of HAS+Hyal1 
transfectants was not correlated with cell cycle or intrinisic proliferation in culture, but 
was commensurate with increased motility, and probably due to altered integrin receptor 
engagement. Consistent with another report, we showed that Hyal1 expression promoted 
cell cycling with higher rate of entry to S-phase and shorter residence in G0/G1 phase, 
while HAS expressing cells resided longer in G0/G1 and consequently were slower to 
enter S-phase. Intracellular and extracellular HA has been reported to play a role in 
mitosis by supporting de-adhesion of cells during mitotic cell rounding. Intracellular HA 
can also impose steric hindrance by inhibiting DNA synthesis unless balanced by 
concurrent Hyal1 expression to promote cell cycling. In chapter 4, our goal was to 
determine the signaling mechanisms underlying altered cell cycle kinetics. Accelerated 
entry and increased fraction of cells in S-phase, in both Hyal1 expressing and 
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Hyal1+HAS3 coexpressing lines, were accompanied by reduced levels of p21. Moreover, 
both p21 and p27 were increased in HAS expressing cells, which could explain their 
reduced DNA synthesis (chapter 4). Further validation of this involvement is required. 
Experiments evaluating the activation of cyclin dependent kinases such as CDK4/6 and 
phosphorylation of Rb during cell cycle progression will throw further light on the effect 
of the CKIs in these cells. 
 
5.2 SIGNIFICANCE 
HA has been suggested to participate in tumor growth and CaP progression1-3, 
consistent with the elevated HA levels around both tumor cell and tumor stroma in tumor 
samples. Overexpression of the HA synthases has shown to promote tumorigenesis in 
many cancer models4-7. None of these studies addressed the involvement of Hyal in such 
processes. The studies described in this report on the contrary suggest that overexpression 
of HA synthases alone is tumor suppressive. We observed maximum tumor growth in 
prostate only by concurrent expression of HAS and Hyal1 (Chapter 2 and 3). This is a 
significant finding, indicating dual requirement of both metabolic enzymes for maximum 
tumorigenesis. We also observed requirement of both HAS and Hyal1 for promoting 
enhanced metastases to lymph nodes, which is a novel finding (Chapter 2 and 3). Our 
studies have also attributed that the enhanced tumor growth, metastatic potential is 
primarily due to effects on cell proliferation, cell cycle, adhesion and motility and not due 
to angiogenesis. This is again intriguing, since overexpression of Hyal1 has previously 
shown to promote angiogenesis. In contrast to our expectation we did not see significant 
correlation between intratumoral vascularity and tumor size and metastatic potential. 
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Since HA influences angiogenesis in a size dependent manner, we need to further 
investigate the size of oligomers generated as a result of co-expression of HAS and 
Hyal1. 
Another significant highlight of our study is the differential effect of exogenous 
HA versus that produced endogenously by synthases. A vast array of study in the 
literature observed effects of exogenous HA on cell proliferation, motility and 
intracellular signaling pathway, whereas our studies failed to identify such a relationship. 
In our system exogenous high molecular weight HA did not elicit growth suppression as 
we observed with endogenous expression of HAS. We also did not see any remarkable 
changes in ERK phosphorylation in presence of exogenous HA (data not shown). This 
discrepancy in findings might be due to variations in cell type specificity, but highlights 
the important role of HAS and endogenous production of HA in tumorigenesis. 
Meanwhile we also observed that exogenous addition hyaluronidase mediated similar 
effects as the co-expression of Hyal1 and HAS, suggesting the source of the 
hyaluronidase could be from stromal compartment. 
From these studies it is enticing to speculate that HAS and Hyal1 might function 
in a chronological order in CaP progression, where initial overexpression of HAS and HA 
production alone can be tumor suppressive either by suppressing tumor cell proliferation, 
but also by suppressing immune response. But subsequently tumor cells might induce 
expression of Hyal to ameliorate the growth suppressive effects and promote aggressive 
disease progression. 
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5.3 FUTURE DIRECTIONS 
The current research has led to several interesting questions, prompting future 
work in the relevant areas. Some of the possible avenues have been outlined below. 
 
5.3.1 Does HA Metabolic Enzymes have a Role in DNA Damage Response? 
The cell cycle progression studies have shown that Hyal1 expressing cells have 
reduced residence time in G0/G1. We also know this can be attributed to reduced levels 
of p21, an important cyclin dependent kinase inhibitor (CKI) that regulates cell cycle 
progression. p21 plays a protective role during DNA damage in normal cells8. The 
expression of p21 is directly induced by the DNA damage sensor p53 in response to 
DNA damaging agents. p21 then causes cell cycle arrest and allows the cell to repair the 
damaged DNA. Cells lacking p21 appear to arrest, but they continue to synthesize their 
DNA. This probably results in abnormal DNA content and genomic instability, 
sometimes but not always leading to cell death by apoptosis9-11. However, p21 also plays 
a role in inhibiting apoptosis, where p21 becomes cytoplasmic during monocytic or 
neuronal differentiation and interacts with pro-apoptotic proteins SAP and ASK1 kinases 
and also prevents procaspase-3 activation, preventing their catalytic activity and 
apoptotic function12-15. The decreased expression of p21 in Hyal1 expressing cells and 
Hyal1+HAS3 co-expressing cells correlates with the increased rate of S-phase entry in 
these cells and also with the enhanced fraction of cells in the S-phase compared to the 
control. Does this mean that these cells are compromised in their DNA damage 
mechanisms and continue to synthesize new DNA, with a higher probability for 
incorporated mutations? Such mutations could then accumulate and result in genomic 
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instability, one of the hallmarks of tumorigenesis and a key underlying factor in tumor 
progression. We are collaborating to explore this aspect by examining DNA damage 
response pathways activated (or not activated) in our prostate tumor cell transfectants, 
and the DNA damage check point proteins in these cells. 
 
5.3.2 Mechanism of p21 Downregulation in Hyal1 Expressing Cells and p27 
Upregulation in HAS Expressing Cells 
The results described in chapter 4 suggest that CKIs p21 and p27 are potential 
candidates for regulation of cell cycling in the prostate tumor cells overexpressing Hyal1, 
HAS3 and Hyal1+HAS3. Out data show p21 protein is downregulated in Hyal1 and 
Hyal1+HAS3 expressing cells, whereas it appears to be modestly elevated in HAS3 
expressing cells along with p27. These preliminary observations raise a number of 
important of questions. First, are the changes in protein levels of p21 and p27 due to 
transcriptional regulation or due to post-translational modification? Protein 
phosphorylation is a key regulatory mechanism employed by cells to regulate function, 
localization and stability of p21 and p2716. Phosphorylation of critical serine (S146) and 
threonine (T145) residues in p21 by kinases such as PKCς (protein kinase C ς) and Akt, 
respectively, affect p21 stability. Furthermore, p21 interacts directly with the proteosome, 
which probably accounts for its ubiquitin-independent degradation, and this may be 
dependent on protein modification16. An interesting aspect of the p21 and p27 group of 
proteins is that they are both unstructured proteins that adopt an ordered structure only 
upon binding to a protein partner17. Thus, another research question is whether Hyal1 
overexpression affects, either directly or indirectly, p21 expression and/or stability. 
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Direct interaction of p21 and Hyal1 leading to decreased p21 stability seems highly 
unlikely, but an indirect mechanism could be mediated through Akt (phosphorylation and 
stabilization) or through p53 (transcriptional regulation). Studies by other groups have 
shown that exogenous HA polymer increases p27 protein level by stabilizing the protein 
in mitogen stimulated vascular smooth muscle cells18. HA polymer mediates this effect in 
these cells by inhibiting mitogen-induced cyclin D1 and reducing the expression of Skp2, 
a protein involved in the degradation of p27. In our experiments, though we observe an 
increase in p27 protein in cells expressing HAS, downregulation of cyclin D1 does not 
occur with HA overproduction. This probably implies two scenarios: there are cell type 
specific differences in cyclin D1 regulation; or the effect of exogenous HA and HA 
synthesized by cells might be quite different, as we and other labs have reported in cell 
proliferation studies. Nevertheless, we see increases in p27 levels in HAS expressing 
cells, implying that other mechanisms may be relevant in our system. 
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